

**Publications of  
Department of Medicine Faculty  
1995 - 2002**

*This is a compilation of articles from PUBMED, and it does not include chapters and abstracts.*

Anderson, Joseph

1: Anderson JC, Birk JW, Shaw RD. Comparison of colonoscopy and double-contrast barium enema. N Engl J Med. 2000 Dec 7;343(23):1729; discussion 1729-30.

2: Anderson JC, Gonzalez JD, Messina CR, Pollack BJ. Factors that predict incomplete colonoscopy: thinner is not always better. Am J Gastroenterol. 2000 Oct;95(10):2784-7.

3: Khan AM, Birk JW, Anderson JC, Georgsson M, Park TL, Smith CJ, Comer GM. A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients. Am J Gastroenterol. 2000 Aug;95(8):1961-6.

4: Anderson JC, Pollack BJ. Predicting of hyperplastic histology by endoscopic features. Gastrointest Endosc. 2000 Jul;52(1):149-50.

5: Anderson JC, Pollack BJ, Shaw RD. Virtual colonoscopy. N Engl J Med. 2000 Mar 9;342(10):738; discussion 738-9.

Bahou, Wadie

1: Sandalon Z, Gnatenko DV, Bahou WF, Hearing P. Adeno-associated virus (AAV) Rep protein enhances the generation of a recombinant mini-adenovirus (Ad) utilizing an Ad/AAV hybrid virus. J Virol. 2000 Nov;74(22):10381-9.

2: Cao J, Hymowitz M, Conner C, Bahou WF, Zucker S. The propeptide domain of membrane type 1-matrix metalloproteinase acts as an intramolecular chaperone when expressed in trans with the mature sequence in COS-1 cells. J Biol Chem. 2000 Sep 22;275(38):29648-53.

3: Joseph K, Nakazawa Y, Bahou WF, Ghebrehiwet B, Kaplan AP. Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Mol Med. 1999 Aug;5(8):555-63.

4: Cao J, Drews M, Lee HM, Conner C, Bahou WF, Zucker S. The 9-kDa N-terminal propeptide domain of MT1-MMP is required for the activation of progelatinase A. Ann N Y Acad Sci. 1999 Jun 30;878:710-2.

5: Cupit LD, Schmidt VA, Bahou WF. Proteolytically activated receptor-3. A member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. Trends Cardiovasc Med. 1999 Jan-Feb;9(1-2):42-8. Review.

- 6: Gnatenko DV, Saenko EL, Jesty J, Cao LX, Hearing P, Bahou WF. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. *Br J Haematol.* 1999 Jan;104(1):27-36.
- 7: Cao J, Drews M, Lee HM, Conner C, Bahou WF, Zucker S. The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A. *J Biol Chem.* 1998 Dec 25;273(52):34745-52.
- 8: Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer JA, Bahou WF. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a Par gene cluster and characterization in vascular endothelial cells and platelets. *J Biol Chem.* 1998 Jun 12;273(24):15061-8.
- 9: Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. *Int J Cancer.* 1998 Mar 2;75(5):780-6.
- 10: Mazzucato M, Marco LD, Masotti A, Pradella P, Bahou WF, Ruggeri ZM. Characterization of the initial alpha-thrombin interaction with glycoprotein Ib alpha in relation to platelet activation. *J Biol Chem.* 1998 Jan 23;273(4):1880-7.
- 11: Bahou WF, Demetrick DJ. The human thrombin receptor gene and the 5q-syndrome. *Leuk Lymphoma.* 1997 Sep;27(1-2):1-10. Review.
- 12: Mirza H, Schmidt VA, Derian CK, Jesty J, Bahou WF. Mitogenic responses mediated through the proteinase-activated receptor-2 are induced by expressed forms of mast cell alpha- or beta-tryptases. *Blood.* 1997 Nov 15;90(10):3914-22.
- 13: Kaufman LD, Bahou WF, Fromowitz FB. Myelodysplasia presenting as monoarthritis. *J Rheumatol.* 1997 Jul;24(7):1446-7. No abstract available.
- 14: Schmidt VA, Nierman WC, Feldblyum TV, Maglott DR, Bahou WF. The human thrombin receptor and proteinase activated receptor-2 genes are tightly linked on chromosome 5q13. *Br J Haematol.* 1997 Jun;97(3):523-9.
- 15: Gnatenko D, Arnold TE, Zolotukhin S, Nuovo GJ, Muzyczka N, Bahou WF. Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells. *J Investig Med.* 1997 Feb;45(2):87-98.
- 16: Arnold TE, Gnatenko D, Bahou WF. In vivo gene transfer into rat arterial walls with novel adeno-associated virus vectors. *J Vasc Surg.* 1997 Feb;25(2):347-55.

- 17: Noiri E, Hu Y, Bahou WF, Keese CR, Giaever I, Goligorsky MS. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells. *J Biol Chem.* 1997 Jan 17;272(3):1747-52.
- 18: King JM, Srivastava KD, Stefano GB, Bilfinger TV, Bahou WF, Magazine HI. Human monocyte adhesion is modulated by endothelin B receptor-coupled nitric oxide release. *J Immunol.* 1997 Jan 15;158(2):880-6.
- 19: Kimura M, Andersen TT, Fenton JW 2nd, Bahou WF, Aviv A. Plasmin-platelet interaction involves cleavage of functional thrombin receptor. *Am J Physiol.* 1996 Jul;271(1 Pt 1):C54-60.
- 20: Peresleni T, Noiri E, Bahou WF, Goligorsky MS. Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. *Am J Physiol.* 1996 Jun;270(6 Pt 2):F971-7.
- 21: Schmidt VA, Vitale E, Bahou WF. Genomic cloning and characterization of the human thrombin receptor gene. Structural similarity to the proteinase activated receptor-2 gene. *J Biol Chem.* 1996 Apr 19;271(16):9307-12.
- 22: Mirza H, Yatsula V, Bahou WF. The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. *J Clin Invest.* 1996 Apr 1;97(7):1705-14.
- 23: Noiri E, Peresleni T, Srivastava N, Weber P, Bahou WF, Peunova N, Goligorsky MS. Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells. *Am J Physiol.* 1996 Mar;270(3 Pt 1):C794-802.
- 24: Demetrick DJ, Dewald GW, Lanman J, Bahou WF. The thrombin receptor gene is centromeric to the common proximal breakpoint in patients with the 5q- syndrome: identification of a previously unrecognized chromosome 5 inversion. *Br J Haematol.* 1996 Feb;92(2):339-43.
- 25: Zucker S, Conner C, DiMassmo BI, Ende H, Drews M, Seiki M, Bahou WF. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. *J Biol Chem.* 1995 Oct 6;270(40):23730-8.
- 26: Meng H, Tonnesen MG, Marchese MJ, Clark RA, Bahou WF, Gruber BL. Mast cells are potent regulators of endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression. *J Cell Physiol.* 1995 Oct;165(1):40-53.

### Barnett, Richard

- 1: Barnett RL, Ruffini L, Ramsammy L, Pasmantier R, Friedlaender MM, Nord EP. cGMP antagonizes angiotensin-mediated phosphatidylcholine hydrolysis and C kinase activation in mesangial cells. *Am J Physiol.* 1995 Feb;268(2 Pt 1):C376-81.

### Birk, John

1: Anderson JC, Birk JW, Shaw RD. Comparison of colonoscopy and double-contrast barium enema. *N Engl J Med.* 2000 Dec 7;343(23):1729; discussion 1729-30.

2: Khan AM, Birk JW, Anderson JC, Georgsson M, Park TL, Smith CJ, Comer GM. A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients. *Am J Gastroenterol.* 2000 Aug;95(8):1961-6.

### Brand, Douglas

1: Cohan GA, Hearney EG, Brand DL. Psychosocial curriculum for a primary care residency. *Acad Med.* 1996 May;71(5):556-7.

2: Praissman M, Brand DL, Praissman LA, Walden M, Fay ME, Lane BP, Manonkian A, Lu YM. Autoradiographic identification of a gastrin receptor on the human parietal cell. *Regul Pept.* 1998 Feb 27;73(3):183-90.

### Carlson, Harold

1: Carlson HE, Kaell AT, Schulman PE, Tan M, Bock JL. Effects of several nonsteroidal antiinflammatory drugs on thyroid function tests. *J Rheumatol.* 1999 Aug;26(8):1855-6.

2: Carlson HE, Graber ML, Gelato MC, Hershman JM. Endocrine effects of erythropoietin. *Int J Artif Organs.* 1995 Jun;18(6):309-14.

### Cersosimo, Eugenio

1: Cersosimo E, Garlick P, Ferretti J. Abnormal glucose handling by the kidney in response to hypoglycemia in type 1 diabetes. *Diabetes.* 2001 Sep;50(9):2087-93.

2: Cersosimo E, Garlick P, Ferretti J. Renal substrate metabolism and gluconeogenesis during hypoglycemia in humans. *Diabetes.* 2000 Jul;49(7):1186-93.

3: Cersosimo E, Garlick P, Ferretti J. Regulation of splanchnic and renal substrate supply by insulin in humans. *Metabolism.* 2000 May;49(5):676-83.

4: Zaitseva I, Ajmal M, Cersosimo E. Application of high-performance liquid chromatography of plasma fatty acids as their phenacyl esters to evaluate splanchnic and renal fatty acid balance in vivo. *J Chromatogr B Biomed Sci Appl.* 1999 Apr 30;727(1-2):15-22.

- 5: Cersosimo E, Garlick P, Ferretti J. Renal glucose production during insulin-induced hypoglycemia in humans. *Diabetes*. 1999 Feb;48(2):261-6.
- 6: Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. *Am J Physiol*. 1999 Jan;276(1 Pt 1):E78-84.
- 7: Cersosimo E, Zaitseva IN, Ajmal M. Effects of beta-adrenergic blockade on hepatic and renal glucose production during hypoglycemia in conscious dogs. *Am J Physiol*. 1998 Nov;275(5 Pt 1):E792-7.
- 8: Cersosimo E, Molina PE, Abumrad NN. Renal lactate metabolism and gluconeogenesis during insulin-induced hypoglycemia. *Diabetes*. 1998 Jul;47(7):1101-6.
- 9: Garlick PJ, Cersosimo E. Techniques for assessing protein and glucose kinetics. *Baillieres Clin Endocrinol Metab*. 1997 Dec;11(4):629-44. Review.
- 10: Cersosimo E, Ajmal M, Naukam RJ, Molina PE, Abumrad NN. Role of the kidney in plasma glucose regulation during hyperglycemia. *Am J Physiol*. 1997 May;272(5 Pt 1):E756-61.
- 11: Cersosimo E, Molina PE, Abumrad NN. Renal glucose production during insulin-induced hypoglycemia. *Diabetes*. 1997 Apr;46(4):643-6.
- 12: Cersosimo E, Danou F, Persson M, Miles JM. Effects of pulsatile delivery of basal growth hormone on lipolysis in humans. *Am J Physiol*. 1996 Jul;271.

#### Chen, Wen-Tien

- 1: Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. *Oncogene*. 2000 Dec 27;19(56):6642-50. Review.
- 2: Cao J, Zhang ZY, Patima, Zhang YX, Chen WT. Human papillomavirus infection and p53 alteration in oral squamous cell carcinoma. *Chin J Dent Res*. 2000 Nov;3(3):44-9.
- 3: Mueller SC, Ghersi G, Akiyama SK, Sang QX, Howard L, Pineiro-Sanchez M, Nakahara H, Yeh Y, Chen WT. A novel protease-docking function of integrin at invadopodia. *J Biol Chem*. 1999 Aug 27;274(35):24947-52.
- 4: Chen WT, Wang JY. Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. *Ann N Y Acad Sci*. 1999 Jun 30;878:361-71. Review.
- 5: Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. *Circ Res*. 1998 Jul 27;83(2):187-95.

6: Nakahara H, Mueller SC, Nomizu M, Yamada Y, Yeh Y, Chen WT. Activation of beta1 integrin signaling stimulates tyrosine phosphorylation of p190RhoGAP and membrane-protrusive activities at invadopodia. *J Biol Chem*. 1998 Jan 2;273(1):9-12.

7: Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen WT. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. *Proc Natl Acad Sci U S A*. 1997 Jul 22;94(15):7959-64.

8: Goldstein LA, Ghersi G, Pineiro-Sanchez ML, Salamone M, Yeh Y, Flessate D, Chen WT. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. *Biochim Biophys Acta*. 1997 Jul 10;1361(1):11-9.

9: Pineiro-Sanchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Chen WT. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. *J Biol Chem*. 1997 Mar 21;272(12):7595-601.

10: Nakahara H, Nomizu M, Akiyama SK, Yamada Y, Yeh Y, Chen WT. A mechanism for regulation of melanoma invasion. Ligation of alpha6beta1 integrin by laminin G peptides. *J Biol Chem*. 1996 Nov 1;271(44):27221-4.

#### Cohan, Gail

1: Cohan GA, Hearney EG, Brand DL. Psychosocial curriculum for a primary care residency. *Acad Med*. 1996 May;71(5):556-7.]

#### Cohn, Peter F

1: Cohn PF. EECF - new data on possible mechanisms of action. *Eur Heart J*. 2001 Aug;22(16):1363-4.

2: Springer S, Fife A, Lawson W, Hui JC, Jandorf L, Cohn PF, Fricchione G. Psychosocial effects of enhanced external counterpulsation in the angina patient: a second study. *Psychosomatics*. 2001 Mar-Apr;42(2):124-32.

4: Cohn PF, Cohn JK. Medical and psychological aspects of hormone replacement therapy in postmenopausal women: points of view from a cardiologist and a psychotherapist. *Clin Cardiol*. 1998 Dec;21(12):875-7.

5: Lawson WE, Hui JC, Guo T, Burger L, Cohn PF. Prior revascularization increases the effectiveness of enhanced external counterpulsation. *Clin Cardiol*. 1998 Nov;21(11):841-4.

6: Cohn PF. Treatment of chronic myocardial ischemia: rationale and treatment options. *Cardiovasc Drugs Ther*. 1998 Oct;12 Suppl 3:217-23. Review.

8: Suresh K, Simandl S, Lawson WE, Hui JC, Lillis O, Burger L, Guo T, Cohn PF. Maximizing the hemodynamic benefit of enhanced external counterpulsation. *Clin Cardiol*. 1998 Sep;21(9):649-53.

9: Cohn PF. Rationale for the use of calcium antagonists in the treatment of silent myocardial ischemia. *Clin Ther*. 1997;19 Suppl A:74-91. Review.

#### Cupit, Lisa

1: Cupit LD, Schmidt VA, Bahou WF. Proteolytically activated receptor-3. A member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. *Trends Cardiovasc Med*. 1999 Jan-Feb;9(1-2):42-8. Review.

2: Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer JA, Bahou WF. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a Par gene cluster and characterization in vascular endothelial cells and platelets. *J Biol Chem*. 1998 Jun 12;273(24):15061-8.

#### DaCosta, Noshir

1: Madajewicz S, Matei D, Hentschel P, Kudelka A, Abel W, Fiore JJ, DaCosta NA, Pendyala L. Actual 5-year survival of patients with stage IIIB breast carcinoma: phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid. *Cancer Invest*. 1999;17(7):463-7.

#### Dattwyler, Raymond

1: Gomes-Solecki MJ, Wormser GP, Persing DH, Berger BW, Glass JD, Yang X, Dattwyler RJ. A first-tier rapid assay for the serodiagnosis of *Borrelia burgdorferi* infection. *Arch Intern Med*. 2001 Sep 10;161(16):2015-20.

2: Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, Rush TJ, Rahn DW, Coyle PK, Persing DH, Fish D, Luft BJ. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. *Clin Infect Dis*. 2000 Jul;31 Suppl 1:1-14.

3: Gomes-Solecki MJ, Dunn JJ, Luft BJ, Castillo J, Dykhuizen DE, Yang X, Glass JD, Dattwyler RJ. Recombinant chimeric *Borrelia* proteins for diagnosis of Lyme disease. *J Clin Microbiol*. 2000 Jul;38(7):2530-5.

4: Seinost G, Golde WT, Berger BW, Dunn JJ, Qiu D, Dunkin DS, Dykhuizen DE, Luft BJ, Dattwyler RJ. Infection with multiple strains of *Borrelia burgdorferi sensu stricto* in patients with Lyme disease. *Arch Dermatol*. 1999 Nov;135(11):1329-33.

- 5: Dattwyler RJ, Gomes-Solecki M. A rapid test for detection of Lyme disease antibodies. *Am Clin Lab.* 1999 Jul;18(6):6.
- 6: Seinost G, Dykhuizen DE, Dattwyler RJ, Golde WT, Dunn JJ, Wang IN, Wormser GP, Schriefer ME, Luft BJ. Four clones of *Borrelia burgdorferi sensu stricto* cause invasive infection in humans. *Infect Immun.* 1999 Jul;67(7):3518-24.
- 7: Seinost G, Gasser R, Reisinger E, Rigler MY, Fischer L, Keplinger A, Dattwyler RJ, Dunn JJ, Klein W. [Cardiac manifestations of Lyme borreliosis with special reference to contractile dysfunction]. *Acta Med Austriaca.* 1998;25(2):44-50. German.
- 8: Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, Grunwaldt E, Agger WA, Franklin M, Oswald D, Cockey L, Maladorno D. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. *N Engl J Med.* 1997 Jul 31;337(5):289-94.
- 9: Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, Masters EJ, Grunwaldt E, Gadgil SD. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. *Ann Intern Med.* 1996 May 1;124(9):785-91.
- 10: Dattwyler RJ, Grunwaldt E, Luft BJ. Clarithromycin in treatment of early Lyme disease: a pilot study. *Antimicrob Agents Chemother.* 1996 Feb;40(2):468-9.

#### Gardner, Pierce

- 1: Peter G, Gardner P. Standards for immunization practice for vaccines in children and adults. *Infect Dis Clin North Am.* 2001 Mar;15(1):9-19. Review.
- 2: Gardner P. Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults. *Infect Dis Clin North Am.* 2001 Mar;15(1):143-53, ix-x. Review.
- 3: Gardner P, Peter G. Recommended schedules for routine immunization of children and adults. *Infect Dis Clin North Am.* 2001 Mar;15(1):1-8. Review.
- 4: Gardner P. Indications for acellular pertussis vaccines in adults: the case for selective, rather than universal, recommendations. *Clin Infect Dis.* 1999 Jun;28 Suppl 2:S131-5.
- 5: Gardner P. Prevention of hepatitis A. *Am J Med.* 1998 Nov;105(5):452-3.
- 6: Gardner P, Eickhoff T. Immunization in adults in the 1990s. *Curr Clin Top Infect Dis.* 1995;15:271-300. Review.
- 7: Gardner P, Tiru CO. Adult immunizations. *Compr Ther.* 1996 Jul;22(7):440-8. Review.
- 8: Gardner P, Eickhoff T, Poland GA, Gross P, Griffin M, LaForce FM, Schaffner W, Strikas R. Adult immunizations. *Ann Intern Med.* 1996 Jan 1;124(1 Pt 1):35-40.

9: Gardner P, LaForce FM. Protection against tetanus. *N Engl J Med.* 1995 Aug 31;333(9):599-600.

Gelato, Marie

1: Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. *J Acquir Immune Defic Syndr.* 2000 Dec 1;25(4):312-21.

2: Gelato MC. The growth hormone/insulin-like growth factor axis in critical illness. *J Pediatr Endocrinol Metab.* 2000 Sep;13 Suppl 2:1023-9. Review.

3: Mynarcik DC, Frost RA, Lang CH, DeCristofaro K, McNurlan MA, Garlick PJ, Steigbigel RT, Fuhrer J, Ahnn S, Gelato MC. Insulin-like growth factor system in patients with HIV infection: effect of exogenous growth hormone administration. *J Acquir Immune Defic Syndr.* 1999 Sep 1;22(1):49-55.

4: McNurlan MA, Garlick PJ, Frost RA, Decristofaro KA, Lang CH, Steigbigel RT, Fuhrer J, Gelato M. Albumin synthesis and bone collagen formation in human immunodeficiency virus-positive subjects: differential effects of growth hormone administration. *J Clin Endocrinol Metab.* 1998 Sep;83(9):3050-5.

5: Garlick PJ, McNurlan MA, Bark T, Lang CH, Gelato MC. Hormonal regulation of protein metabolism in relation to nutrition and disease. *J Nutr.* 1998 Feb;128(2 Suppl):356S-359S. Review.

6: Gelato MC, Frost RA. IGFBP-3. Functional and structural implications in aging and wasting syndromes. *Endocrine.* 1997 Aug;7(1):81-5. Review.

7: McNurlan MA, Garlick PJ, Steigbigel RT, DeCristofaro KA, Frost RA, Lang CH, Johnson RW, Santasier AM, Cabahug CJ, Fuhrer J, Gelato MC. Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease. *J Clin Invest.* 1997 Oct 15;100(8):2125-32.

8: Frost RA, Lang CH, Gelato MC. Transient exposure of human myoblasts to tumor necrosis factor-alpha inhibits serum and insulin-like growth factor-I stimulated protein synthesis. *Endocrinology.* 1997 Oct;138(10):4153-9.

9: Lang CH, Pollard V, Fan J, Traber LD, Traber DL, Frost RA, Gelato MC, Prough . Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin. *Am J Physiol.* 1997 Jul;273(1 Pt 2):R371-8.

10: Castells S, Beaulieu I, Torrado C, Wisniewski KE, Zarny S, Gelato MC. Hypothalamic versus pituitary dysfunction in Down's syndrome as cause of growth retardation. *J Intellect Disabil Res.* 1996 Dec;40 ( Pt 6):509-17.

- 11: Bereket A, Wilson TA, Blethen SL, Fan J, Frost RA, Gelato MC, Lang CH. Effect of short-term fasting on free/dissociable insulin-like growth factor I concentrations in normal human serum. *J Clin Endocrinol Metab.* 1996 Dec;81(12):4379-84.
- 12: Samstein B, Hoimes ML, Fan J, Frost RA, Gelato MC, Lang CH. IL-6 stimulation of insulin-like growth factor binding protein (IGFBP)-1 production. *Biochem Biophys Res Commun.* 1996 Nov 12;228(2):611-5.
- 13: Frost RA, Nachman SA, Lang CH, Gelato MC. Proteolysis of insulin-like growth factor-binding protein-3 in human immunodeficiency virus-positive children who fail to thrive. *J Clin Endocrinol Metab.* 1996 Aug;81(8):2957-62.
- 14: Lang CH, Fan J, Frost RA, Gelato MC, Sakurai Y, Herndon DN, Wolfe RR. Regulation of the insulin-like growth factor system by insulin in burn patients. *J Clin Endocrinol Metab.* 1996 Jul;81(7):2474-80.
- 15: Frost RA, Fuhrer J, Steigbigel R, Mariuz P, Lang CH, Gelato MC. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. *Clin Endocrinol (Oxf).* 1996 May;44(5):501-14.
- 16: Gelato MC. Aging and immune function: a possible role for growth hormone. *Horm Res.* 1996;45(1-2):46-9. Review.
- 17: Fan J, Char D, Bagby GJ, Gelato MC, Lang CH. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor. *Am J Physiol.* 1995 Nov;269(5 Pt 2):R1204-12.
- 18: April MM, Heimann A, Jung LU, Gelato MC. Follicular variant of papillary carcinoma with hyperthyroidism. *Otolaryngol Head Neck Surg.* 1995 Nov;113(5):628-31.
- 19: Fan J, Char D, Kolasa AJ, Pan W, Maitra SR, Patlak CS, Spolarics Z, Gelato MC, Lang CH. Alterations in hepatic production and peripheral clearance of IGF-I after endotoxin. *Am J Physiol.* 1995 Jul;269(1 Pt 1):E33-42.
- 20: Carlson HE, Graber ML, Gelato MC, Hershman JM. Endocrine effects of erythropoietin. *Int J Artif Organs.* 1995 Jun;18(6):309-14.
- 21: Wojnar MM, Fan J, Frost RA, Gelato MC, Lang CH. Alterations in the insulin-like growth factor system in trauma patients. *Am J Physiol.* 1995 Apr;268(4 Pt 2):R970-7.
- 22: Bereket A, Lang CH, Blethen SL, Gelato MC, Fan J, Frost RA, Wilson TA. Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. *J Clin Endocrinol Metab.* 1995 Apr;80(4):1312-7.

Ghebrehiwet, Berhane

- 1: Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA, Henson PM. C1q and mannose binding lectin engagement of cell surface calreticulin and cd91 initiates macropinocytosis and uptake of apoptotic cells. *J Exp Med*. 2001 Sep 17;194(6):781-96.
- 2: Ghebrehiwet B, Lim BL, Kumar R, Feng X, Peerschke EI. gC1q-R/p33, a member of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation and infection. *Immunol Rev*. 2001 Apr;180:65-77.
- 3: Peerschke EI, Ghebrehiwet B. Human blood platelet gC1qR/p33. *Immunol Rev*. 2001 Apr;180:56-64.
- 4: Szabo J, Cervenak L, Toth FD, Prohaszka Z, Horvath L, Kerekes K, Beck Z, Bacsi A, Erdei A, Peerschke EI, Fust G, Ghebrehiwet B. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures. *Clin Immunol*. 2001 May;99(2):222-31.
- 5: Kaplan AP, Joseph K, Shibayama Y, Reddigari S, Ghebrehiwet B. Activation of the plasma kinin forming cascade along cell surfaces. *Int Arch Allergy Immunol*. 2001 Jan-Mar;124(1-3):339-42.
- 6: Tye AJ, Ghebrehiwet B, Guo N, Sastry KN, Chow BK, Peerschke EI, Lim BL. The human gC1qR/p32 gene, C1qBP. Genomic organization and promoter analysis. *J Biol Chem*. 2001 May 18;276(20):17069-75.
- 7: Joseph K, Ghebrehiwet B, Kaplan AP. Activation of the kinin-forming cascade on the surface of endothelial cells. *Biol Chem*. 2001 Jan;382(1):71-5.
- 8: Joseph K, Shibayama Y, Ghebrehiwet B, Kaplan AP. Factor XII-dependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1. *Thromb Haemost*. 2001 Jan;85(1):119-24.
- 9: Storz P, Hausser A, Link G, Dedio J, Ghebrehiwet B, Pfizenmaier K, Johannes FJ. Protein kinase C [micro] is regulated by the multifunctional chaperon protein p32. *J Biol Chem*. 2000 Aug 11;275(32):24601-7.
- 10: Braun L, Ghebrehiwet B, Cossart P. gC1q-R/p32, a C1q-binding protein, is a receptor for the InlB invasion protein of *Listeria monocytogenes*. *EMBO J*. 2000 Apr 3;19(7):1458-66.
- 11: Nguyen T, Ghebrehiwet B, Peerschke EI. Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. *Infect Immun*. 2000 Apr;68(4):2061-8.

- 12: Joseph K, Shibayama Y, Nakazawa Y, Peerschke EI, Ghebrehwet B, Kaplan AP. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease. *Immunopharmacology*. 1999 Sep;43(2-3):203-10. Review.
- 13: Joseph K, Nakazawa Y, Bahou WF, Ghebrehwet B, Kaplan AP. Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. *Mol Med*. 1999 Aug;5(8):555-63.
- 14: Joseph K, Ghebrehwet B, Kaplan AP. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. *Clin Immunol*. 1999 Sep;92(3):246-55.
- 15: Guo WX, Ghebrehwet B, Weksler B, Schweitzer K, Peerschke EI. Up-regulation of endothelial cell binding proteins/receptors for complement component C1q by inflammatory cytokines. *J Lab Clin Med*. 1999 Jun;133(6):541-50.
- 16: Lu PD, Galanakis DK, Ghebrehwet B, Peerschke EI. The receptor for the globular "heads" of C1q, gC1q-R, binds to fibrinogen/fibrin and impairs its polymerization. *Clin Immunol*. 1999 Mar;90(3):360-7.
- 17: Kaplan AP, Joseph K, Shibayama Y, Nakazawa Y, Ghebrehwet B, Reddigari S, Silverberg M. Bradykinin formation. Plasma and tissue pathways and cellular interactions. *Clin Rev Allergy Immunol*. 1998 Winter;16(4):403-29. Review.
- 18: Peerschke EI, Ghebrehwet B. Platelet receptors for the complement component C1q: implications for hemostasis and thrombosis. *Immunobiology*. 1998 Aug;199(2):239-49. Review.
- 19: Ghebrehwet B, Peerschke EI. Structure and function of gC1q-R: a multiligand binding cellular protein. *Immunobiology*. 1998 Aug;199(2):225-38. Review.
- 20: Bronson R, Bronson S, Oula L, Zhang W, Ghebrehwet B. Detection of complement C1q receptors on human spermatozoa. *J Reprod Immunol*. 1998 Apr;38(1):1-14.
- 21: Tan X, Wong ST, Ghebrehwet B, Storm DR, Bordin S. Complement C1q inhibits cellular spreading and stimulates adenylyl cyclase activity of fibroblasts. *Clin Immunol Immunopathol*. 1998 May;87(2):193-204.
- 22: Peerschke EI, Jesty J, Reid KB, Ghebrehwet B. The soluble recombinant form of a binding protein/receptor for the globular domain of C1q (gC1qR) enhances blood coagulation. *Blood Coagul Fibrinolysis*. 1998 Jan;9(1):29-37.
- 23: Lim BL, White RA, Hummel GS, Schwaeble W, Lynch NJ, Peerschke EI, Reid KB, Ghebrehwet B. Characterization of the murine gene of gC1qBP, a novel cell protein that binds the globular heads of C1q, vitronectin, high molecular weight kininogen and factor XII. *Gene*. 1998 Mar 16;209(1-2):229-37.

- 24: Peerschke EI, Ghebrehwet B. C1q augments platelet activation in response to aggregated Ig. *J Immunol*. 1997 Dec 1;159(11):5594-8.
- 25: Leigh LE, Ghebrehwet B, Perera TP, Bird IN, Strong P, Kishore U, Reid KB, Eggleton P. C1q-mediated chemotaxis by human neutrophils: involvement of gC1qR and G-protein signalling mechanisms. *Biochem J*. 1998 Feb 15;330 ( Pt 1):247-54.
- 26: Lynch NJ, Reid KB, van den Berg RH, Daha MR, Leigh LA, Ghebrehwet B, Lim WB, Schwaeble WJ. Characterisation of the rat and mouse homologues of gC1qBP, a 33 kDa glycoprotein that binds to the globular 'heads' of C1q. *FEBS Lett*. 1997 Nov 24;418(1-2):111-4.
- 27: Kaplan AP, Joseph K, Shibayama Y, Reddigari S, Ghebrehwet B, Silverberg M. The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. *Adv Immunol*. 1997;66:225-72. Review.
- 28: Ghebrehwet B, Lu PD, Zhang W, Keilbaugh SA, Leigh LE, Eggleton P, Reid KB, Peerschke EI. Evidence that the two C1q binding membrane proteins, gC1q-R and cC1q-R, associate to form a complex. *J Immunol*. 1997 Aug 1;159(3):1429-36.
- 29: Prohaszka Z, Nemes J, Hidvegi T, Toth FD, Kerekes K, Erdei A, Szabo J, Ujhelyi E, Thielens N, Dierich MP, Spath P, Ghebrehwet B, Hampl H, Kiss J, Arlaud G, Fust G. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. *AIDS*. 1997 Jul;11(8):949-58.
- 30: Peterson KL, Zhang W, Lu PD, Keilbaugh SA, Peerschke EI, Ghebrehwet B. The C1q-binding cell membrane proteins cC1q-R and gC1q-R are released from activated cells: subcellular distribution and immunochemical characterization. *Clin Immunol Immunopathol*. 1997 Jul;84(1):17-26.
- 31: Guo N, Weremowicz S, Lynch N, Lim BL, Schwaeble W, Peerschke EI, Morton CC, Reid KB, Ghebrehwet B, Sastry KN. Assignment of C1QBP encoding the C1q globular domain binding protein (gC1q-R) to human chromosome 17 band p13.3 by in situ hybridization. *Cytogenet Cell Genet*. 1997;77(3-4):283-4.
- 32: Peerschke EI, Smyth SS, Teng EI, Dalzell M, Ghebrehwet B. Human umbilical vein endothelial cells possess binding sites for the globular domain of C1q. *J Immunol*. 1996 Nov 1;157(9):4154-8.
- 33: Lim BL, Reid KB, Ghebrehwet B, Peerschke EI, Leigh LA, Preissner KT. The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor. *J Biol Chem*. 1996 Oct 25;271(43):26739-44.
- 34: Ghebrehwet B, Lu PD, Zhang W, Lim BL, Eggleton P, Leigh LE, Reid KB, Peerschke EI.

Identification of functional domains on gC1q-R, a cell surface protein that binds to the globular "heads" of C1q, using monoclonal antibodies and synthetic peptides. *Hybridoma*. 1996 Oct;15(5):333-42.

35: Kuna P, Iyer M, Peerschke EI, Kaplan AP, Reid KB, Ghebrehiwet B. Human C1q induces eosinophil migration. *Clin Immunol Immunopathol*. 1996 Oct;81(1):48-54.

36: Joseph K, Ghebrehiwet B, Peerschke EI, Reid KB, Kaplan AP. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). *Proc Natl Acad Sci U S A*. 1996 Aug 6;93(16):8552-7.

37: Ghebrehiwet B, Kew RR, Gruber BL, Marchese MJ, Peerschke EI, Reid KB. Murine mast cells express two types of C1q receptors that are involved in the induction of chemotaxis and chemokinesis. *J Immunol*. 1995 Sep 1;155(5):2614-9.

38: Eggleton P, Ghebrehiwet B, Sastry KN, Coburn JP, Zaner KS, Reid KB, Tauber AI. Identification of a gC1q-binding protein (gC1q-R) on the surface of human neutrophils. Subcellular localization and binding properties in comparison with the cC1q-R. *J Clin Invest*. 1995 Apr;95(4):1569-78.

### Goligorsky, Michael

1: Brodsky S, Chen J, Lee A, Akassoglou K, Norman J, Goligorsky MS. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. *Am J Physiol Heart Circ Physiol*. 2001 Oct;281(4):H1784-92.

2: Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, Brodsky S, Goligorsky M. Scavenging of peroxynitrite ameliorates lipid peroxidation and DNA damage in experimental ischemic acute renal failure. *Am J Physiol Renal Physiol*. 2001 Jul 12

3: Chen J, Brodsky S, Li H, Hampel DJ, Miyata T, Weinstein T, Gafter U, Norman JT, Fine LG, Goligorsky MS. Delayed branching of endothelial capillary-like cords in glycated collagen I is mediated by early induction of PAI-1. *Am J Physiol Renal Physiol*. 2001 Jul;281(1):F71-80.

4: Goligorsky MS. Vascular endothelial growth factor: molecular underpinning from development of vasculature to development of disease. *Am J Physiol Cell Physiol*. 2001 Jun;280(6):C1357. Review.

5: Hampel DJ, Sansome C, Sha M, Brodsky S, Lawson WE, Goligorsky MS. Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration. *J Am Soc Nephrol*. 2001 May;12(5):1026-35.

6: Goligorsky MS. The concept of cellular "fight-or-flight" reaction to stress. *Am J Physiol Renal Physiol*. 2001 Apr;280(4):F551-61. Review.

- 7: Goligorsky MS, Chen J, Brodsky S. Workshop: endothelial cell dysfunction leading to diabetic nephropathy : focus on nitric oxide. *Hypertension*. 2001 Feb;37(2 Part 2):744-8. Review.
- 8: Goligorsky MS, Chen J, Brodsky S. Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. *Hypertension*. 2001 Feb;37(2):744-8. Review.
- 9: Brodsky SV, Morrishow AM, Dharia N, Gross SS, Goligorsky MS. Glucose scavenging of nitric oxide. *Am J Physiol Renal Physiol*. 2001 Mar;280(3):F480-6.
- 10: Li H, Brodsky S, Basco M, Romanov V, De Angelis DA, Goligorsky MS. Nitric oxide attenuates signal transduction: possible role in dissociating caveolin-1 scaffold. *Circ Res*. 2001 Feb 2;88(2):229-36.
- 11: Tseng L, Mazella J, Goligorsky MS, Rialas CM, Stefano GB. Dopamine and morphine stimulate nitric oxide release in human endometrial glandular epithelial cells. *J Soc Gynecol Investig*. 2000 Nov-Dec;7(6):343-7.
- 12: Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. *Am J Physiol Renal Physiol*. 2000 Oct;279(4):F671-8.
- 13: Goligorsky MS. Endothelial cell dysfunction and nitric oxide synthase. *Kidney Int*. 2000 Sep;58(3):1360-76. No abstract available.
- 14: Goligorsky MS. Making sense out of oxygen sensor. *Circ Res*. 2000 Apr 28;86(8):824-6.
- 15: Goligorsky MS, Noiri E, Tsukahara H, Budzikowski AS, Li H. A pivotal role of nitric oxide in endothelial cell dysfunction. *Acta Physiol Scand*. 2000 Jan;168(1):33-40. Review.
- 16: Thorup C, Jones CL, Gross SS, Moore LC, Goligorsky MS. Carbon monoxide induces vasodilation and nitric oxide release but suppresses endothelial NOS. *Am J Physiol*. 1999 Dec;277(6 Pt 2):F882-9.
- 17: Noiri E, Dickman K, Miller F, Romanov G, Romanov VI, Shaw R, Chambers AF, Rittling SR, Denhardt DT, Goligorsky MS. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. *Kidney Int*. 1999 Jul;56(1):74-82.
- 18: Goligorsky MS, Abedi H, Noiri E, Takhtajan A, Lense S, Romanov V, Zachary I. Nitric oxide modulation of focal adhesions in endothelial cells. *Am J Physiol*. 1999 Jun;276(6 Pt 1):C1271-81.
- 19: Goligorsky MS, Noiri E. Duality of nitric oxide in acute renal injury. *Semin Nephrol*. 1999 May;19(3):263-71. Review.
- 20: Romanov VI, Goligorsky MS. RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro. *Prostate*. 1999 May;39(2):108-18.

- 21: Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. *Clin Exp Pharmacol Physiol*. 1999 Mar;26(3):269-71. Review.
- 22: Thorup C, Kornfeld M, Goligorsky MS, Moore LC. AT1 receptor inhibition blunts angiotensin II-stimulated nitric oxide release in renal arteries. *J Am Soc Nephrol*. 1999 Jan;10 Suppl 11:S220-4.
- 23: Goligorsky MS, Noiri E, Kessler H, Romanov V. Therapeutic effect of arginine-glycine-aspartic acid peptides in acute renal injury. *Clin Exp Pharmacol Physiol*. 1998 Mar-Apr;25(3-4):276-9. Review.
- 24: Goligorsky MS, Kessler H, Romanov VI. Molecular mimicry of integrin ligation: therapeutic potential of arginine-glycine-aspartic acid (RGD) peptides. *Nephrol Dial Transplant*. 1998 Feb;13(2):254-63. Review
- 25: Thorup C, Kornfeld M, Winaver JM, Goligorsky MS, Moore LC. Angiotensin-II stimulates nitric oxide release in isolated perfused renal resistance arteries. *Pflugers Arch*. 1998 Feb;435(3):432-4.
- 26: Noiri E, Lee E, Testa J, Quigley J, Colflesh D, Keese CR, Giaever I, Goligorsky MS. Podokinesis in endothelial cell migration: role of nitric oxide. *Am J Physiol*. 1998 Jan;274(1 Pt 1):C236-44.
- 27: Suh H, Wadhwa NK, Peresleni T, McNurlan M, Garlick P, Goligorsky MS. Decreased L-arginine during peritonitis in ESRD patients on peritoneal dialysis. *Adv Perit Dial*. 1997;13:205-9.
- 28: Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore LC. Production and physiological actions of anandamide in the vasculature of the rat kidney. *J Clin Invest*. 1997 Sep 15;100(6):1538-46.
- 29: Goligorsky MS, Iijima K, Krivenko Y, Tsukahara H, Hu Y, Moore LC. Role of mesangial cells in macula densa to afferent arteriole information transfer. *Clin Exp Pharmacol Physiol*. 1997 Jul;24(7):527-31. Review.
- 30: Romanov V, Noiri E, Czerwinski G, Finsinger D, Kessler H, Goligorsky MS. Two novel probes reveal tubular and vascular Arg-Gly-Asp (RGD) binding sites in the ischemic rat kidney. *Kidney Int*. 1997 Jul;52(1):93-102.
- 31: Epstein M, Goligorsky MS. Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. *J Nephrol*. 1997 May-Jun;10(3):120-35. Review.
- 32: Suh H, Peresleni T, Wadhwa N, McNurlan M, Garlick P, Goligorsky MS. Amino acid profile and nitric oxide pathway in patients on continuous ambulatory peritoneal dialysis: L-arginine depletion in acute peritonitis. *Am J Kidney Dis*. 1997 May;29(5):712-9.

- 33: Goligorsky MS, Noiri E, Kessler H, Romanov V. Therapeutic potential of RGD peptides in acute renal injury. *Kidney Int.* 1997 May;51(5):1487-92. Review.
- 34: Wang Y, Goligorsky MS, Lin M, Wilcox JN, Marsden PA. A novel, testis-specific mRNA transcript encoding an NH<sub>2</sub>-terminal truncated nitric-oxide synthase. *J Biol Chem.* 1997 Apr 25;272(17):11392-401.
- 35: Wang Hy, Goligorsky MS, Malbon CC. Temporal activation of Ca<sup>2+</sup>-calmodulin-sensitive protein kinase type II is obligate for adipogenesis. *J Biol Chem.* 1997 Jan 17;272(3):1817-21.
- 36: Noiri E, Hu Y, Bahou WF, Keese CR, Giaever I, Goligorsky MS. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells. *J Biol Chem.* 1997 Jan 17;272(3):1747-52.
- 37: Noiri E, Goligorsky MS, Wang GJ, Wang J, Cabahug CJ, Sharma S, Rhodes BA, Som P. Biodistribution and clearance of <sup>99m</sup>Tc-labeled Arg-Gly-Asp (RGD) peptide in rats with ischemic acute renal failure. *J Am Soc Nephrol.* 1996 Dec;7(12):2682-8.
- 38: Goligorsky MS, Noiri E, Peresleni T, Hu Y. Role of nitric oxide in cell adhesion and locomotion. *Exp Nephrol.* 1996 Nov-Dec;4(6):314-21. Review.
- 39: da Silva JL, Morishita T, Escalante B, Staudinger R, Drummond G, Goligorsky MS, Lutton JD, Abraham NG. Dual role of heme oxygenase in epithelial cell injury: contrasting effects of short-term and long-term exposure to oxidant stress. *J Lab Clin Med.* 1996 Sep;128(3):290-6.
- 40: Stefano GB, Liu Y, Goligorsky MS. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. *J Biol Chem.* 1996 Aug 9;271(32):19238-42.
- 41: Peresleni T, Noiri E, Bahou WF, Goligorsky MS. Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. *Am J Physiol.* 1996 Jun;270(6 Pt 2):F971-7.
- 42: Noiri E, Peresleni T, Miller F, Goligorsky MS. In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. *J Clin Invest.* 1996 May 5;97(10):2377-83.
- 43: Noiri E, Romanov V, Czerwinski G, Gailit J, DiBona GF, Som P, Oster Z, Goligorsky MS. Adhesion molecules and tubular obstruction in acute renal failure. *Ren Fail.* 1996 May;18(3):513-5.
- 44: Noiri E, Peresleni T, Srivastava N, Weber P, Bahou WF, Peunova N, Goligorsky MS. Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells. *Am J Physiol.* 1996 Mar;270(3 Pt 1):C794-802.

45: Tseng L, Zhang J, Peresleni TYu, Goligorsky MS. Cyclic expression of endothelial nitric oxide synthase mRNA in the epithelial glands of human endometrium. *J Soc Gynecol Investig.* 1996 Jan-Feb;3(1):33-8.

46: Stefano GB, Hartman A, Bilfinger TV, Magazine HI, Liu Y, Casares F, Goligorsky MS. Presence of the mu3 opiate receptor in endothelial cells. Coupling to nitric oxide production and vasodilation. *J Biol Chem.* 1995 Dec 22;270(51):30290-3.

47: Noiri E, Romanov V, Forest T, Gailit J, DiBona GF, Miller F, Som P, Oster ZH, Goligorsky MS. Pathophysiology of renal tubular obstruction: therapeutic role of synthetic RGD peptides in acute renal failure. *Kidney Int.* 1995 Nov;48(5):1375-85. Review.

48: Goligorsky MS, Colflesh D, Gordienko D, Moore LC. Branching points of renal resistance arteries are enriched in L-type calcium channels and initiate vasoconstriction. *Am J Physiol.* 1995 Feb;268(2 Pt 2):F251-7.

#### Gruber, Barry

1: Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. *Arthritis Rheum.* 2001 Jan;44(1):202-11.

2: Hasni SA, Gruber BL. Sarcoidosis presenting as necrotizing sinus destruction mimicking Wegener's granulomatosis. *J Rheumatol.* 2000 Feb;27(2):512-4.

3: Zhang J, Gruber BL, Marchese MJ, Zucker S, Schwartz LB, Kew RR. Mast cell tryptase does not alter matrix metalloproteinase expression in human dermal fibroblasts: further evidence that proteolytically-active tryptase is a potent fibrogenic factor. *J Cell Physiol.* 1999 Nov;181(2):312-8.

4: Gruber BL, Taub E. Thermal and EMG biofeedback learning in nonhuman primates. *Appl Psychophysiol Biofeedback.* 1998 Mar;23(1):1-12.

5: Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. *J Clin Invest.* 1997 Jun 1;99(11):2691-700.

6: Gruber BL, Schranz JA, Fuhrer J, Kane PB. Isolated pulmonary microangiitis mimicking pneumonia in a patient infected with human immunodeficiency virus. *J Rheumatol.* 1997 Apr;24(4):759-62.

7: Gruber BL, Kew RR, Jelaska A, Marchese MJ, Garlick J, Ren S, Schwartz LB, Korn JH.

Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. *J Immunol.* 1997 Mar 1;158(5):2310-7.

8: Scioscia KA, Miller F, April MM, Gruber BL. Growth factors in subglottic stenosis. *Ann Otol Rhinol Laryngol.* 1996 Dec;105(12):936-43.

9: Sorbi D, French DL, Nuovo GJ, Kew RR, Arbeit LA, Gruber BL. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. *Arthritis Rheum.* 1996 Oct;39(10):1747-53.

10: Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, Arbeit LA. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. *Clin Immunol Immunopathol.* 1996 Feb;78(2):161-71.

11: Meng H, Marchese MJ, Garlick JA, Jelaska A, Korn JH, Gailit J, Clark RA, Gruber BL. Mast cells induce T-cell adhesion to human fibroblasts by regulating intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression. *J Invest Dermatol.* 1995 Dec;105(6):789-96.

12: Meng H, Tonnesen MG, Marchese MJ, Clark RA, Bahou WF, Gruber BL. Mast cells are potent regulators of endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression. *J Cell Physiol.* 1995 Oct;165(1):40-53.

13: Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast-cell migration. *Blood.* 1995 Oct 1;86(7):2488-93. PMID: 7545457

14: Ghebrehiwet B, Kew RR, Gruber BL, Marchese MJ, Peerschke EI, Reid KB. Murine mast cells express two types of C1q receptors that are involved in the induction of chemotaxis and chemokinesis. *J Immunol.* 1995 Sep 1;155(5):2614-9.

15: Gruber BL. Mast cells: accessory cells which potentiate fibrosis. *Int Rev Immunol.* 1995;12(2-4):259-79. Review. No abstract available.

### Jesty, Joylon

1: Beltrami E, Jesty J. The role of membrane patch size and flow in regulating a proteolytic feedback threshold on a membrane: possible application in blood coagulation. *Math Biosci.* 2001 Jul;172(1):1-13.

2: Gnatenko DV, Saenko EL, Jesty J, Cao LX, Hearing P, Bahou WF. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. *Br J Haematol.* 1999 Jan;104(1):27-36.

- 3: Peerschke EI, Jesty J, Reid KB, Ghebrehiwet B. The soluble recombinant form of a binding protein/receptor for the globular domain of C1q (gC1qR) enhances blood coagulation. *Blood Coagul Fibrinolysis*. 1998 Jan;9(1):29-37.
- 4: Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. *Int J Cancer*. 1998 Mar 2;75(5):780-6.
- 5: Mirza H, Schmidt VA, Derian CK, Jesty J, Bahou WF. Mitogenic responses mediated through the proteinase-activated receptor-2 are induced by expressed forms of mast cell alpha- or beta-tryptases. *Blood*. 1997 Nov 15;90(10):3914-22.
- 6: Jesty J, Lorenz A, Rodriguez J, Wun TC. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. *Blood*. 1996 Mar 15;87(6):2301-7.
- 7: Beltrami E, Jesty J. Mathematical analysis of activation thresholds in enzyme-catalyzed positive feedbacks: application to the feedbacks of blood coagulation. *Proc Natl Acad Sci U S A*. 1995 Sep 12;92(19):8744-8.
- 8: Martin DW, Jesty J. Calcium stimulation of procoagulant activity in human erythrocytes. ATP dependence and the effects of modifiers of stimulation and recovery. *J Biol Chem*. 1995 May 5;270(18):10468-74.

#### Lin, Richard

- 1: Ballou LM, Tian PY, Lin HY, Jiang YP, Lin RZ. Dual regulation of glycogen synthase kinase-3{beta} by the {alpha}{sub1A} adrenergic receptor. *J Biol Chem*. 2001 Aug 31
- 2: Jiang YP, Ballou LM, Lin RZ. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver. *J Biol Chem*. 2001 Apr 6;276(14):10943-51.
- 3: Rybkin II, Cross ME, McReynolds EM, Lin RZ, Ballou LM. alpha(1A) adrenergic receptor induces eukaryotic initiation factor 4E-binding protein 1 phosphorylation via a Ca(2+)-dependent pathway independent of phosphatidylinositol 3-kinase/Akt. *J Biol Chem*. 2000 Feb 25;275(8):5460-5.
- 4: Ballou LM, Cross ME, Huang S, McReynolds EM, Zhang BX, Lin RZ. Differential regulation of the phosphatidylinositol 3-kinase/Akt and p70 S6 kinase pathways by the alpha(1A)-adrenergic receptor in rat-1 fibroblasts. *J Biol Chem*. 2000 Feb 18;275(7):4803-9.

#### Luft, Benjamin

- 1: Younus F, Luft BJ. Vaccines for Lyme disease. *Curr Clin Top Infect Dis*. 2001;21:349-65.
- 2: Leport C, Franck J, Chene G, Derouin F, Ecobichon JL, Pueyo S, Miro JM, Luft BJ, Morlat P, Dumon H. Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus. *Clin Diagn Lab Immunol*. 2001 May;8(3):579-84.
- 3: Jacobson JM, Hafner R, Remington J, Farthing C, Holden-Wiltse J, Bosler EM, Harris C, Jayaweera DT, Roque C, Luft BJ. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. *AIDS*. 2001 Mar 30;15(5):583-9.
- 4: Kumaran D, Eswaramoorthy S, Luft BJ, Koide S, Dunn JJ, Lawson CL, Swaminathan S. Crystal structure of outer surface protein C (OspC) from the Lyme disease spirochete, *Borrelia burgdorferi*. *EMBO J*. 2001 Mar 1;20(5):971-8.
- 5: Ding W, Huang X, Yang X, Dunn JJ, Luft BJ, Koide S, Lawson CL. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. *J Mol Biol*. 2000 Oct 6;302(5):1153-64.
- 6: Luft BJ, Chua A. Central Nervous System Toxoplasmosis in HIV Pathogenesis, Diagnosis, and Therapy. *Curr Infect Dis Rep*. 2000 Aug;2(4):358-362.
- 7: Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, Rush TJ, Rahn DW, Coyle PK, Persing DH, Fish D, Luft BJ. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. *Clin Infect Dis*. 2000 Jul;31 Suppl 1:1-14.
- 8: Gomes-Solecki MJ, Dunn JJ, Luft BJ, Castillo J, Dykhuizen DE, Yang X, Glass JD, Dattwyler RJ. Recombinant chimeric *Borrelia* proteins for diagnosis of Lyme disease. *J Clin Microbiol*. 2000 Jul;38(7):2530-5.
- 9: Seinost G, Golde WT, Berger BW, Dunn JJ, Qiu D, Dunkin DS, Dykhuizen DE, Luft BJ, Dattwyler RJ. Infection with multiple strains of *Borrelia burgdorferi sensu stricto* in patients with Lyme disease. *Arch Dermatol*. 1999 Nov;135(11):1329-33.
- 10: Huang X, Link K, Koide A, Dunn JJ, Luft BJ, Koide S. 1H, 13C, and 15N NMR backbone assignments of 37 kDa surface antigen OspC from *Borrelia burgdorferi*. *J Biomol NMR*. 1999 Jul;14(3):283-4.
- 11: Seinost G, Dykhuizen DE, Dattwyler RJ, Golde WT, Dunn JJ, Wang IN, Wormser GP, Schriefer ME, Luft BJ. Four clones of *Borrelia burgdorferi sensu stricto* cause invasive infection in humans. *Infect Immun*. 1999 Jul;67(7):3518-24.
- 12: Wang IN, Dykhuizen DE, Qiu W, Dunn JJ, Bosler EM, Luft BJ. Genetic diversity of ospC in a local population of *Borrelia burgdorferi sensu stricto*. *Genetics*. 1999 Jan;151(1):15-30.

- 13: Huang X, Yang X, Luft BJ, Koide S. NMR identification of epitopes of Lyme disease antigen OspA to monoclonal antibodies. *J Mol Biol.* 1998 Aug 7;281(1):61-7.
- 14: Chene G, Morlat P, Leport C, Hafner R, Dequae L, Charreau I, Aboulker JP, Luft B, Aubertin J, Vilde JL, Salamon R. Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. *Controlled Clinical Trials.* 19(3):233-48, 1998 Jun.
- 15: Qiu WG, Bosler EM, Campbell JR, Ugine GD, Wang IN, Luft BJ, Dykhuizen DE. A population genetic study of *Borrelia burgdorferi sensu stricto* from eastern Long Island, New York, suggested frequency-dependent selection, gene flow and host adaptation. *Hereditas.* 1997;127(3):203-16.
- 16: Piesman J, Dolan MC, Happ CM, Luft BJ, Rooney SE, Mather TN, Golde WT. Duration of immunity to reinfection with tick-transmitted *Borrelia burgdorferi* in naturally infected mice. *Infect Immun.* 1997 Oct;65(10):4043-7.
- 17: Silverman JA, Hayes ML, Luft BJ, Joiner KA. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology. *Antimicrob Agents Chemother.* 1997 Sep;41(9):1859-66.
- 18: Schutzer SE, Coyle PK, Krupp LB, Deng Z, Belman AL, Dattwyler R, Luft BJ. Simultaneous expression of *Borrelia* OspA and OspC and IgM response in cerebrospinal fluid in early neurologic Lyme disease. *J Clin Invest.* 1997 Aug 15;100(4):763-7.
- 19: Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, Grunwaldt E, Agger WA, Franklin M, Oswald D, Cockey L, Maladorno D. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. *N Engl J Med.* 1997 Jul 31;337(5):289-94.
- 20: Pueyo S, Salmi LR, Chene G, Leport C, Morlat P, Dequae L, Gregoire V, Hafner R, Vilde JL, Luft BJ, Aubertin J, Salamon R. Survival after AIDS-defining events in patients with  $< 200$  lymphocytes CD4+ x  $10^6/L$  who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1997 Apr 15;14(5):459-64.
- 21: Li H, Dunn JJ, Luft BJ, Lawson CL. Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. *Proc Natl Acad Sci U S A.* 1997 Apr 15;94(8):3584-9.
- 22: Rousseau F, Pueyo S, Morlat P, Hafner R, Chene G, Leport C, Luft BJ, Miro J, Aubertin J, Salamon R, Vilde JL. Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group. *Clin Infect Dis.* 1997 Mar;24(3):396-402.

- 23: Mariuz P, Bosler EM, Luft BJ. Toxoplasma pneumonia. *Semin Respir Infect.* 1997 Mar;12(1):40-3.
- 24: Derouin F. Leport C. Pueyo S. Morlat P. Letrillart B. Chene G. Ecobichon JL. Luft B. Aubertin J. Hafner R. Vilde JL. Salamon R. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. *AIDS.* 10(13):1521-7, 1996 Nov.
- 25: Lyubsky S. Gavrilovskaya I. Luft B. Mackow E. Histopathology of Peromyscus leucopus naturally infected with pathogenic NY-1 hantaviruses: pathologic markers of HPS viral infection in mice. *Laboratory Investigation.* 74(3):627-33, 1996 Mar.
- 26: Jacobson JM, Davidian M, Rainey PM, Hafner R, Raasch RH, Luft BJ. Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. *Antimicrob Agents Chemother.* 1996 Jun;40(6):1360-5.
- 27: Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, Masters EJ, Grunwaldt E, Gadgil SD. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. *Ann Intern Med.* 1996 May 1;124(9):785-91.
- 28: Guttman DS, Wang PW, Wang IN, Bosler EM, Luft BJ, Dykhuizen DE. Multiple infections of Ixodes scapularis ticks by Borrelia burgdorferi as revealed by single-strand conformation polymorphism analysis. *J Clin Microbiol.* 1996 Mar;34(3):652-6.
- 29: Dattwyler RJ, Grunwaldt E, Luft BJ. Clarithromycin in treatment of early Lyme disease: a pilot study. *Antimicrob Agents Chemother.* 1996 Feb;40(2):468-9.
- 30: Leport C, Chene G, Morlat P, Luft BJ, Rousseau F, Pueyo S, Hafner R, Miro J, Aubertin J, Salamon R, Vilde JL. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. *J Infect Dis.* 1996 Jan;173(1):91-7.
- 31: Coyle PK, Schutzer SE, Deng Z, Krupp LB, Belman AL, Benach JL, Luft BJ. Detection of Borrelia burgdorferi-specific antigen in antibody-negative cerebrospinal fluid in neurologic Lyme disease. *Neurology.* 1995 Nov;45(11):2010-5.
- 32: Richards FO Jr, Kovacs JA, Luft BJ. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. *Clin Infect Dis.* 1995 Aug;21 Suppl 1:S49-56. Review.
- 32: McGrath BC, Dunn JJ, Gorgone G, Guttman D, Dykhuizen D, Luft BJ. Identification of an immunologically important hypervariable domain of major outer surface protein A of Borrelia burgdorferi. *Infect Immun.* 1995 Apr;63(4):1356-61.
- 32: Mackow ER, Luft BJ, Bosler E, Goldgaber D. More on hantavirus in New England and New York. *N Engl J Med.* 1995 Feb 2;332(5):337-8.

33: Beckers CJ, Roos DS, Donald RG, Luft BJ, Schwab JC, Cao Y, Joiner KA. Inhibition of cytoplasmic and organellar protein synthesis in *Toxoplasma gondii*. Implications for the target of macrolide antibiotics. *J Clin Invest*. 1995 Jan;95(1):367-76.

Mackow, Eric

1: Drebot MA, Gavrilovskaya I, Mackow ER, Chen Z, Lindsay R, Sanchez AJ, Nichol ST, Artsob H. Genetic and serotypic characterization of Sin Nombre-like viruses in Canadian *Peromyscus maniculatus* mice. *Virus Res*. 2001 May;75(1):75-86.

2: LaMonica R, Kocer SS, Nazarova J, Dowling W, Geimonen E, Shaw RD, Mackow ER. VP4 differentially regulates TRAF2 signaling, disengaging JNK activation while directing NF-kappa B to effect rotavirus-specific cellular responses. *J Biol Chem*. 2001 Jun 8;276(23):19889-96.

3: Mackow ER, Gavrilovskaya IN. Cellular receptors and hantavirus pathogenesis. *Curr Top Microbiol Immunol*. 2001;256:91-115. Review.

4: Dowling W, Denisova E, LaMonica R, Mackow ER. Selective membrane permeabilization by the rotavirus VP5\* protein is abrogated by mutations in an internal hydrophobic domain. *J Virol*. 2000 Jul;74(14):6368-76.

5: Rollo EE, Kumar KP, Reich NC, Cohen J, Angel J, Greenberg HB, Sheth R, Anderson J, Oh B, Hempson SJ, Mackow ER, Shaw RD. The epithelial cell response to rotavirus infection. *J Immunol*. 1999 Oct 15;163(8):4442-52.

6: Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. *J Virol*. 1999 May;73(5):3951-9.

7: Denisova E, Dowling W, LaMonica R, Shaw R, Scarlata S, Ruggeri F, Mackow ER. Rotavirus capsid protein VP5\* permeabilizes membranes. *J Virol*. 1999 Apr;73(4):3147-53.

8: Gavrilovskaya I, LaMonica R, Fay ME, Hjelle B, Schmaljohn C, Shaw R, Mackow ER. New York 1 and Sin Nombre viruses are serotypically distinct viruses associated with hantavirus pulmonary syndrome. *J Clin Microbiol*. 1999 Jan;37(1):122-6.

9: Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. *Proc Natl Acad Sci U S A*. 1998 Jun 9;95(12):7074-9.

10: Ludert JE, Mason BB, Angel J, Tang B, Hoshino Y, Feng N, Vo PT, Mackow EM, Ruggeri FM, Greenberg HB. Identification of mutations in the rotavirus protein VP4 that alter sialic-acid-dependent infection. *J Gen Virol*. 1998 Apr;79 ( Pt 4):725-9.

- 11: Giammarioli AM, Mackow ER, Fiore L, Greenberg HB, Ruggeri FM. Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus. *Virology*. 1996 Nov 1;225(1):97-110.
- 12: Sheth R, Anderson J, Sato T, Oh B, Hempson SJ, Rollo E, Mackow ER, Shaw RD. Rotavirus stimulates IL-8 secretion from cultured epithelial cells. *Virology*. 1996 Jul 15;221(2):251-9.
- 13: Lyubsky S, Gavrilovskaya I, Luft B, Mackow E. Histopathology of *Peromyscus leucopus* naturally infected with pathogenic NY-1 hantaviruses: pathologic markers of HPS viral infection in mice. *Lab Invest*. 1996 Mar;74(3):627-33.
- 14: Song JW, Baek LJ, Gavrilovskaya IN, Mackow ER, Hjelle B, Yanagihara R. Sequence analysis of the complete S genomic segment of a newly identified hantavirus isolated from the white-footed mouse (*Peromyscus leucopus*): phylogenetic relationship with other sigmodontine rodent-borne hantaviruses. *Virus Genes*. 1996;12(3):249-56.
- 15: Hjelle B, Lee SW, Song W, Torrez-Martinez N, Song JW, Yanagihara R, Gavrilovskaya I, Mackow ER. Molecular linkage of hantavirus pulmonary syndrome to the white-footed mouse, *Peromyscus leucopus*: genetic characterization of the M genome of New York virus. *J Virol*. 1995 Dec;69(12):8137-41.
- 16: Shaw RD, Hempson SJ, Mackow ER. Rotavirus diarrhea is caused by nonreplicating viral particles. *J Virol*. 1995 Oct;69(10):5946-50.
- 17: Fiore L, Dunn SJ, Ridolfi B, Ruggeri FM, Mackow ER, Greenberg HB. Antigenicity, immunogenicity and passive protection induced by immunization of mice with baculovirus-expressed VP7 protein from rhesus rotavirus. *J Gen Virol*. 1995 Aug;76 ( Pt 8):1981-8.
- 18: Mackow ER, Luft BJ, Bosler E, Goldgaber D. More on hantavirus in New England and New York. *N Engl J Med*. 1995 Feb 2;332(5):337-8. No abstract available.

#### Madajewicz, Stefan

- 1: Madajewicz S, Hentschel P, Burns P, Caruso R, Fiore J, Fried M, Malhotra H, Ostrow S, Sugarman S, Viola M. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. *J Clin Oncol*. 2000 Oct 15;18(20):3553-7.
- 2: Madajewicz S, Chowhan N, Tfayli A, Roque C, Meek A, Davis R, Wolf W, Cabahug C, Roche P, Manzione J, Iliya A, Shady M, Hentschel P, Atkins H, Braun A. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. *Cancer*. 2000 May 15;88(10):2350-6.

- 3: Madajewicz S, Matei D, Hentschel P, Kudelka A, Abel W, Fiore JJ, DaCosta NA, Pendyala L. Actual 5-year survival of patients with stage IIIB breast carcinoma: phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid. *Cancer Invest.* 1999;17(7):463-7.
- 4: Spector JJ, Lester EP, Chevlen EM, Sciortino D, Harvey JH, Whaley W, Madajewicz S, Isaacs R, Homesley HD, Yee S, Beck TM, Tchekmedyian NS, Crawford KH, Ames M, Creed MR. A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy. *Oncologist.* 1998;3(6):432-438.
- 5: Tfayli A, Hentschel P, Madajewicz S, Manzione J, Chowhan N, Davis R, Roche P, Iliya A, Roque C, Meek A, Shady M. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. *J Neurooncol.* 1999 Mar;42(1):73-7.
- 6: Srivastava SC, Atkins HL, Krishnamurthy GT, Zanzi I, Silberstein EB, Meinken G, Mausner LF, Swailem F, D'Alessandro T, Cabahug CJ, Lau Y, Park T, Madajewicz S. Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. *Clin Cancer Res.* 1998 Jan;4(1):61-8.
- 7: Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. *Clin Ther.* 1996 Jul-Aug;18(4):778-88.
- 8: Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. *Clin Ther.* 1996 May-Jun;18(3):508-18.
- 9: Matei D, Hagag N, Madajewicz S, Chowhan N, Hentschel P, Avvento L, Burns P, Fiore J, Lipera W, Zarrabi H. Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma. *Cancer.* 1995 Oct 15;76(8):1330-5.
- 10: Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. *J Clin Oncol.* 1995 Sep;13(9):2408-16.

#### Mazumder, Amitabha

- 1: Wu A, Mazumder A, Martuza RL, Liu X, Thein M, Meehan KR, Rabkin SD. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. *Cancer Res.* 2001 Apr 1;61(7):3009-15.

- 2: Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD, Boyer M, Cirenza E, Mazumder A, Gehan E, Cahill R, Frankel S, Schultz K. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. *Biol Blood Marrow Transplant.* 2000;6(3A):327-34.
- 3: Wu AG, Michejda M, Mazumder A, Meehan KR, Menendez FA, Tchabo JG, Slack R, Johnson MP, Bellanti JA. Analysis and characterization of hematopoietic progenitor cells from fetal bone marrow, adult bone marrow, peripheral blood, and cord blood. *Pediatr Res.* 1999 Aug;46(2):163-9.
- 4: Posey JA, Raspet R, Verma U, Deo YM, Keller T, Marshall JL, Hodgson J, Mazumder A, Hawkins MJ. A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. *J Immunother.* 1999 Jul;22(4):371-9.
- 5: Wu AG, Liu X, Mazumder A, Bellanti JA, Meehan KR. Improvement of gene transduction efficiency in T lymphocytes using retroviral vectors. *Hum Gene Ther.* 1999 Apr 10;10(6):977-82.
- 6: Meehan KR, Arun B, Gehan EA, Berberian B, Sulica V, Areman EM, Mazumder A, Lippman ME. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. *Bone Marrow Transplant.* 1999 Apr;23(7):667-73.
- 7: Areman EM, Rhodes PL, Mazumder A, Meehan KR. Differential effects of IL-2 incubation on hematopoietic potential of autologous bone marrow and mobilized PBSC from patients with hematologic malignancies. *J Hematother.* 1999 Feb;8(1):39-44.
- 8: Verma UN, van den Blink B, Pillai R, Chawla J, Mazumder A, Herscovitz HB, Meehan KR. Paclitaxel vs cyclophosphamide in peripheral blood stem cell mobilization: comparative studies in a murine model. *Exp Hematol.* 1999 Mar;27(3):553-60.
- 9: Mazumder A. Experimental evidence of interleukin-2 activity in bone marrow transplantation. *Cancer J Sci Am.* 1997 Dec;3 Suppl 1:S37-42. Review.
- 10: Meehan KR, Verma UN, Cahill R, Frankel S, Areman EM, Sacher RA, Foelber R, Rajagopal C, Gehan EA, Lippman ME, Mazumder A. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates. *Bone Marrow Transplant.* 1997 Oct;20(8):643-51.

### Morrison, Sidonie

- 1: Morrison SA, Pearson SL, Steigbigel RT. Anti-F(ab')<sub>2</sub> antibody in HIV type 1 infection: relationship to hypergammaglobulinemia and to antibody specific to the V3 loop region of glycoprotein 120. *AIDS Res Hum Retroviruses.* 1998 Apr 10;14(6):491-8.
- 2: Moorjani H, Craddock BP, Morrison SA, Steigbigel RT. Impairment of phagosome-lysosome fusion in HIV-1-infected macrophages. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996 Sep;13(1):18-22.

3: Handley MA, Steigbigel RT, Morrison SA. A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. *J Virol.* 1996 Jul;70(7):4451-6.

Nord, Edward

1: Becker JL, Miller F, Nuovo GJ, Josepovitz C, Schubach WH, Nord EP. Epstein-Barr virus infection of renal proximal tubule cells: possible role in chronic interstitial nephritis. *J Clin Invest.* 1999 Dec;104(12):1673-81.

2: Gulati MS, Miller F, Nord EP. Pauci-immune rapidly progressive glomerulonephritis after nephrectomy in a renal donor. *Am J Kidney Dis.* 1999 Feb;33(2):E9.

3: Nord EP. Role of endothelin in acute renal failure. *Blood Purif.* 1997;15(4-6):273-85. Review.

4: Nord EP. Signalling pathways activated by endothelin stimulation of renal cells. *Clin Exp Pharmacol Physiol.* 1996 Apr;23(4):331-6. Review.

5: Chow LH, Subramanian S, Nuovo GJ, Miller F, Nord EP. Endothelin receptor mRNA expression in renal medulla identified by in situ RT-PCR. *Am J Physiol.* 1995 Sep;269(3 Pt 2):F449-57.

6: Vernace MA, Mento PF, Maita ME, Girardi EP, Chang MD, Nord EP, Wilkes BM. Osmolar regulation of endothelin signaling in rat renal medullary interstitial cells. *J Clin Invest.* 1995 Jul;96(1):183-91.

7: Barnett RL, Ruffini L, Ramsammy L, Pasmantier R, Friedlaender MM, Nord EP. cGMP antagonizes angiotensin-mediated phosphatidylcholine hydrolysis and C kinase activation in mesangial cells. *Am J Physiol.* 1995 Feb;268(2 Pt 1):C376-81.

Novotny, Howard

Sauter G, Gasser TC, Moch H, Richter J, Jiang F, Albrecht R, Novotny H, Wagner U, Bubendorf L, Mihatsch MJ. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. *Urol Res.* 1997;25 Suppl 1:S37-43.

O'Hearn, Daniel

1: Schneider H, O'Hearn DJ, Leblanc K, Smith PL, O'Donnell CP, Eisele DW, Peter JH, Schwartz AR. High-flow transtracheal insufflation treats obstructive sleep apnea. A pilot study. *Am J Respir Crit Care Med.* 2000 Jun;161(6):1869-76.

2: O'Hearn DJ, Leiferman KM, Askin F, Georas SN. Pulmonary infiltrates after cytokine therapy for stem cell transplantation. Massive deposition of eosinophil major basic protein detected by immunohistochemistry. *Am J Respir Crit Care Med.* 1999 Oct;160(4):1361-5.

3: Punjabi NM, O'hearn DJ, Neubauer DN, Nieto FJ, Schwartz AR, Smith PL, Bandeen-Roche K. Modeling hypersomnolence in sleep-disordered breathing. A novel approach using survival analysis. *Am J Respir Crit Care Med.* 1999 Jun;159(6):1703-9.

4: Gavett SH, O'Hearn DJ, Karp CL, Patel EA, Schofield BH, Finkelman FD, Wills-Karp M. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. *Am J Physiol.* 1997 Feb;272(2 Pt 1):L253-61.

5: Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. *J Exp Med.* 1995 Nov 1;182(5):1527-36.

#### O'Riordan, Thomas

1: O'Riordan TG. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. *Respir Care.* 2000 Jul;45(7):836-45. Review.

2: Sabater JR, Mao YM, Shaffer C, James MK, O'Riordan TG, Abraham WM. Aerosolization of P2Y(2)-receptor agonists enhances mucociliary clearance in sheep. *J Appl Physiol.* 1999 Dec;87(6):2191-6.

3: Kemp JP, DeGraff AC Jr, Pearlman DS, Wang Y, Arledge TE, Welch MB, O'Riordan TG, Herrle MR, Stahl EG. A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine. *J Allergy Clin Immunol.* 1999 Dec;104(6):1189-97.

4: O'Riordan T, Faris M. Inhaled antimicrobial therapy. *Respir Care Clin N Am.* 1999 Dec;5(4):617-31. Review.

5: O'Riordan TG, Weinstein MD, Mao Y. Bench testing of nebulizers: a comparison of three methods. *J Aerosol Med.* 1999 Summer;12(2):59-66.

6: Wright CD, Havill AM, Middleton SC, Kashem MA, Lee PA, Dripps DJ, O'Riordan TG, Bevilacqua MP, Abraham WM. Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. *J Pharmacol Exp Ther.* 1999 May;289(2):1007-14.

7: O'Riordan TG, Mao Y, Otero R, Lopez J, Sabater JR, Abraham WM. Budesonide affects allergic mucociliary dysfunction. *J Appl Physiol.* 1998 Sep;85(3):1086-91.

8: Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. *Crit Care Med.* 1998 Jan;26(1):31-9.

9: O'Riordan TG, Amram JC. Effect of nebulizer configuration on delivery of aerosolized tobramycin. *J Aerosol Med.* 1997 Spring;10(1):13-23.

- 10: O'Riordan TG, Otero R, Mao Y, Lauredo I, Abraham WM. Elastase contributes to antigen-induced mucociliary dysfunction in ovine airways. *Am J Respir Crit Care Med.* 1997 May;155(5):1522-8.
- 11: Wanner A, Salathe M, O'Riordan TG. Mucociliary clearance in the airways. *Am J Respir Crit Care Med.* 1996 Dec;154(6 Pt 1):1868-902. Review.
- 12: Salathe M, O'Riordan TG, Wanner A. Treatment of mucociliary dysfunction. *Chest.* 1996 Oct;110(4):1048-57. Review.
- 13: Sabater JR, Otero R, Abraham WM, Wanner A, O'Riordan TG. Endothelin-1 depresses tracheal mucus velocity in ovine airways via ET-A receptors. *Am J Respir Crit Care Med.* 1996 Aug;154(2 Pt 1):341-5.
- 14: Iacono AT, Keenan RJ, Duncan SR, Smaldone GC, Dauber JH, Paradis IL, Ohori NP, Grgurich WF, Burckart GJ, Zeevi A, Delgado E, O'Riordan TG, Zendarsky MM, Yousem SA, Griffith BP. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. *Am J Respir Crit Care Med.* 1996 Apr;153(4 Pt 1):1451-5.
- 15: Palmer LB, Smaldone GC, Simon S, O'Riordan T, Morra L. Tracheal aspirates in long-term mechanically ventilated patients. A human model of gram-negative infection and airway inflammation. *Chest.* 1995 Nov;108(5):1326-32.
- 16: O'Riordan TG, Iacono A, Keenan RJ, Duncan SR, Burckart GJ, Griffith BP, Smaldone GC. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. *Am J Respir Crit Care Med.* 1995 Feb;151(2 Pt 1):516-21.

#### Palmer, Lucy

- 1: Palmer LB, Albulak K, Fields S, Filkin AM, Simon S, Smaldone GC. Oral clearance and pathogenic oropharyngeal colonization in the elderly. *Am J Respir Crit Care Med.* 2001 Aug 1;164(3):464-8.
- 2: Smaldone GC, Palmer LB. Aerosolized antibiotics: current and future. *Respir Care.* 2000 Jun;45(6):667-75. Review.
- 3: Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. *Crit Care Med.* 1998 Jan;26(1):31-9.
- 4: Diot P, Palmer LB, Smaldone A, DeCelie-Germana J, Grimson R, Smaldone GC. RhDNase I aerosol deposition and related factors in cystic fibrosis. *Am J Respir Crit Care Med.* 1997 Nov;156(5):1662-8.
- 5: Diot P, Palmer LB, Uy LL, Albulaak MK, Bonitch L, Smaldone GC. Technique for measurement of oropharyngeal clearance in the elderly. *J Aerosol Med.* 1995 Summer;8(2):177-86.

6: Cabahug CJ, McPeck M, Palmer LB, Cuccia A, Atkins HL, Smaldone GC. Utility of technetium-99m-DTPA in determining regional ventilation. *J Nucl Med.* 1996 Feb;37(2):239-44.

7: Palmer LB, Smaldone GC, Simon S, O'Riordan T, Morra L. Tracheal aspirates in long-term mechanically ventilated patients. A human model of gram-negative infection and airway inflammation. *Chest.* 1995 Nov;108(5):1326-32.

8: Palmer LB, Donelan SV, Fox G, Bellemore E, Greene WH. Gastric flora in chronically mechanically ventilated patients. Relationship to upper and lower airway colonization. *Am J Respir Crit Care Med.* 1995 Apr;151(4):1063-7.

### Rajapakse, Ramona

1: Rajapakse R, Korelitz BI. Inflammatory Bowel Disease During Pregnancy. Current treatment options in gastroenterology.. 2001 Jun;4(3):245-251.

2: Rajapakse R, Warman J, Korelitz BI. Colchicine for persistent constipation after total abdominal colectomy with ileorectostomy for colonic inertia. *J Clin Gastroenterol.* 2001 Jul;33(1):81-4.

3: Korelitz BI, Rajapakse R. Ulcerative duodenitis with ulcerative colitis: is it Crohn's disease or really ulcerative colitis? *J Clin Gastroenterol.* 2001 Feb;32(2):97.

4: Korelitz BI, Rajapakse RO. Further evidence that 6-MP taken by the father with IBD provides risk of congenital anomaly to the pregnancy. *Am J Gastroenterol.* 2001 Jan;96(1):252. No abstract available.

5: Korelitz BI, Rajapakse RO, Zlatanovic J, Baiocco PJ, Gleim GW. 6MP for fathers with IBD at the time of conception: the value of a large clinical experience over unrelated controls. *Am J Gastroenterol.* 2000 Sep;95(9):2386-7.

6: Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. *Am J Gastroenterol.* 2000 Aug;95(8):1949-54.

7: Rajapakse RO, Korelitz BI, Zlatanovic J, Baiocco PJ, Gleim GW. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. *Am J Gastroenterol.* 2000 Mar;95(3):684-8.

8: Atapattu DN, Arseculeratne SN, Rajapakse RP, Perera NA, Eriyagama NB. Purification of the endospores and sporangia of *Rhinosporidium seeberi* on Percoll columns. *Mycopathologia.* 1999;145(3):113-9.

### Sachs, John

- 1: Martin DW, Sachs JR. Ligands presumed to label high affinity and low affinity ATP binding sites do not interact in an (alpha beta)<sub>2</sub> diprotomer in duck nasal gland Na<sup>+</sup>,K<sup>+</sup>-ATPase, nor Do the sites coexist in native enzyme. *J Biol Chem*. 2000 Aug 11;275(32):24512-7.
- 2: Martin DW, Marecek J, Scarlata S, Sachs JR. Alphabeta protomers of Na<sup>+</sup>,K<sup>+</sup>-ATPase from microsomes of duck salt gland are mostly monomeric: formation of higher oligomers does not modify molecular activity. *Proc Natl Acad Sci U S A*. 2000 Mar 28;97(7):3195-200.
- 3: Sachs JR, Martin DW. Role of polyamine structure in inhibition of K<sup>+</sup>-Cl<sup>-</sup> cotransport in human red cell ghosts. *J Physiol*. 1999 Nov 1;520 Pt 3:723-35.
- 4: Martin DW, Sachs JR. Preparation of Na<sup>+</sup>,K<sup>+</sup>-ATPase with near maximal specific activity and phosphorylation capacity: evidence that the reaction mechanism involves all of the sites. *Biochemistry*. 1999 Jun 8;38(23):7485-97.

#### Said, Sami

- 1: Filippatos GS, Gangopadhyay N, Lalude O, Parameswaran N, Said SI, Spielman W, Uhal BD. Regulation of apoptosis by vasoactive peptides. *Am J Physiol Lung Cell Mol Physiol*. 2001 Oct;281(4):L749-61.
- 2: Said SI, Dey RD, Dickman K. Glutamate signalling in the lung. *Trends Pharmacol Sci*. 2001 Jul;22(7):344-5.
- 3: Said SI. The Viktor Mutt Memorial Lecture. Protection by VIP and related peptides against cell death and tissue injury. *Ann N Y Acad Sci*. 2000;921:264-74.
- 4: Said SI, Dickman KG. Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide. *Regul Pept*. 2000 Sep 25;93(1-3):21-9.
- 5: Said SI, Pakbaz H, Berisha HI, Raza S. NMDA receptor activation: critical role in oxidant tissue injury. *Free Radic Biol Med*. 2000 Apr 15;28(8):1300-2.
- 6: Said SI, Bodanszky M. Secretin treatment for autism. *N Engl J Med*. 2000 Apr 20;342(16):1217-8.
- 7: Said SI. VIP and PACAP in pain and inflammation. *Trends Pharmacol Sci*. 2000 Feb;21(2):57.
- 8: Foda HD, Rollo EE, Brown P, Pakbaz H, Berisha H, Said SI, Zucker S. Attenuation of oxidant-induced lung injury by the synthetic matrixmetalloproteinase inhibitor BB-3103. *Ann N Y Acad Sci*. 1999 Jun 30;878:650-3.
- 9: Said SI. Glutamate receptors and asthmatic airway disease. *Trends Pharmacol Sci*. 1999 Apr;20(4):132-4.

- 10: Said SI, Raza S, Berisha HI. Enhancement of systemic and pulmonary vasoconstriction by beta-amyloid peptides and its suppression by vasoactive intestinal peptide. *Ann N Y Acad Sci.* 1998 Dec 11;865:582-5.
- 11: Said SI, Dickman K, Dey RD, Bandyopadhyay A, De Stefanis P, Raza S, Pakbaz H, Berisha HI. Glutamate toxicity in the lung and neuronal cells: prevention or attenuation by VIP and PACAP. *Ann N Y Acad Sci.* 1998 Dec 11;865:226-37.
- 12: Maruno K, Absood A, Said SI. Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo. *Proc Natl Acad Sci U S A.* 1998 Nov 24;95(24):14373-8.
- 13: Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. *Pharmacol Rev.* 1998 Jun;50(2):265-70.
- 14: Robertson BS, Satterfield BE, Said SI, Dey RD. N-methyl-D-aspartate receptors are expressed by intrinsic neurons of rat larynx and esophagus. *Neurosci Lett.* 1998 Mar 13;244(2):77-80.
- 15: Jaeger E, Bauer S, Joyce MW, Foda HD, Berisha HI, Said SI. Structure-activity studies on VIP: IV. The synthetic agonist helodermin-fragment-(1-28)-amide is a potent VIP-agonist with prolonged duration of tracheal relaxant activity. *Ann N Y Acad Sci.* 1996 Dec 26;805:499-504.
- 16: Maruno K, Said SI. VIP inhibits the proliferation of small-cell and nonsmall-cell lung carcinoma. *Ann N Y Acad Sci.* 1996 Dec 26;805:389-92; discussion 392-3.
- 17: Said SI. Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. *Ann N Y Acad Sci.* 1996 Dec 26;805:379-87; discussion 387-8.
- 18: Shima K, Sakakibara H, Said SI. Characterization of VIP-and helodermin-preferring receptors on rat platelets. *Regul Pept.* 1996 Jul 5;63(2-3):99-103.
- 19: Said SI. Molecules that protect: the defense of neurons and other cells. *J Clin Invest.* 1996 May 15;97(10):2163-4.
- 20: Said SI, Berisha HI, Pakbaz H. Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. *Proc Natl Acad Sci U S A.* 1996 May 14;93(10):4688-92.
- 21: Dey RD, Altemus JB, Rodd A, Mayer B, Said SI, Coburn RF. Neurochemical characterization of intrinsic neurons in ferret tracheal plexus. *Am J Respir Cell Mol Biol.* 1996 Mar;14(3):207-16.
- 22: Maruno K, Absood A, Said SI. VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. *Am J Physiol.* 1995 Jun;268(6 Pt 1):L1047-51.

23: Alessandrini F, Sasaki S, Said SI, Lodi R, LoCicero J 3rd. Enhancement of extended lung preservation with a vasoactive intestinal peptide-enriched University of Wisconsin solution. Transplantation. 1995 May 15;59(9):1253-8.

24: Foda HD, Said SI. Nitric oxide and VIP as co-transmitters of neurogenic relaxation of human airways. Am J Respir Crit Care Med. 1995 May;151(5):1689-90.

25: Maggi CA, Giachetti A, Dey RD, Said SI. Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins. Physiol Rev. 1995 Apr;75(2):277-322.

26: Said SI, Berisha HI, Pakbaz H. N-methyl-D-aspartate receptors outside the central nervous system: activation causes acute lung injury that is mediated by nitric oxide synthesis and prevented by vasoactive intestinal peptide. Neuroscience. 1995 Apr;65(4):943-6.

27: Foda HD, Sharaf HH, Absood A, Said SI. Pituitary adenylate cyclase-activating peptide (PACAP), a VIP-like peptide, has prolonged airway smooth muscle relaxant activity. Peptides. 1995;16(6):1057-61.

#### Smaldone, Gerry

1: Smaldone GC. Deposition and clearance: unique problems in the proximal airways and oral cavity in the young and elderly. Respir Physiol. 2001 Oct;128(1):33-8.

2: Palmer LB, Albulak K, Fields S, Filkin AM, Simon S, Smaldone GC. Oral clearance and pathogenic oropharyngeal colonization in the elderly. Am J Respir Crit Care Med. 2001 Aug 1;164(3):464-8.

3: Smaldone GC. Physiological and pathological considerations for aerosol deposition: expiration and models of deposition. J Aerosol Med. 2000 Winter;13(4):387-91.

4: Nikander K, Denyer J, Everard M, Smaldone GC. Validation of a new breathing simulator generating and measuring inhaled aerosol with adult breathing patterns. J Aerosol Med. 2000 Summer;13(2):139-46.

5: Smaldone GC, Palmer LB. Aerosolized antibiotics: current and future. Respir Care. 2000 Jun;45(6):667-75. Review

6: Dolovich MA, MacIntyre NR, Anderson PJ, Camargo CA Jr, Chew N, Cole CH, Dhand R, Fink JB, Gross NJ, Hess DR, Hickey AJ, Kim CS, Martonen TB, Pierson DJ, Rubin BK, Smaldone GC. Consensus statement: aerosols and delivery devices. American Association for Respiratory Care. Respir Care. 2000 Jun;45(6):589-96. Review.

- 7: Stys T, Lawson WE, Smaldone GC, Stys A. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? *Arch Intern Med.* 2000 May 22;160(10):1409-13. Review.
- 8: Dolovich M, Smaldone GC. Estimating the particle size characteristics of therapeutic aerosols. *J Aerosol Med.* 1999 Winter;12(4):215-6.
- 9: Nikander K, Denyer J, Smaldone GC. Effects of equipment dead space and pediatric breathing patterns on inhaled mass of nebulized budesonide. *J Aerosol Med.* 1999 Summer;12(2):67-73.
- 10: Smaldone GC. Airway secretion and asthma. *Respiration.* 1999;66(2):110-1. Review.
- 11: Smaldone GC. [Aerosols in pediatrics: present and future]. *Arch Pediatr.* 1999;6 Suppl 2:172s-173s. French.
- 12: Finlay WH, Smaldone GC. Hygroscopic behavior of nebulized aerosols: not as important as we thought? *J Aerosol Med.* 1998 Winter;11(4):193-5.
- 13: Smaldone GC. Aerosolized bronchodilators in the intensive care unit: much ado about nothing? *Am J Respir Crit Care Med.* 1999 Apr;159(4 Pt 1):1029-30.
- 14: Lavietes MH, Smeltzer SC, Cook SD, Modak RM, Smaldone GC. Airway dynamics, oesophageal pressure and cough. *Eur Respir J.* 1998 Jan;11(1):156-61.
- 15: Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. *Crit Care Med.* 1998 Jan;26(1):31-9.
- 16: Diot P, Palmer LB, Smaldone A, DeCelie-Germana J, Grimson R, Smaldone GC. RhDNase I aerosol deposition and related factors in cystic fibrosis. *Am J Respir Crit Care Med.* 1997 Nov;156(5):1662-8.
- 17: Smaldone GC, Diot P, Groth M, Ilowite J. Respirable mass: vague and indefinable in disease. *J Aerosol Med.* 1998;11 Suppl 1:S105-11.
- 18: Iacono AT, Smaldone GC, Keenan RJ, Diot P, Dauber JH, Zeevi A, Burckart GJ, Griffith BP. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. *Am J Respir Crit Care Med.* 1997 May;155(5):1690-8.
- 19: Tandon R, McPeck M, Smaldone GC. Measuring nebulizer output. Aerosol production vs gravimetric analysis. *Chest.* 1997 May;111(5):1361-5.
- 20: McPeck M, Tandon R, Hughes K, Smaldone GC. Aerosol delivery during continuous nebulization. *Chest.* 1997 May;111(5):1200-5.
- 21: Keenan RJ, Iacono A, Dauber JH, Zeevi A, Yousem SA, Ohori NP, Burckart GJ, Kawai A, Smaldone GC, Griffith BP. Treatment of refractory acute allograft rejection with aerosolized

cyclosporine in lung transplant recipients. *J Thorac Cardiovasc Surg.* 1997 Feb;113(2):335-40; discussion 340-1.

22: Smaldone GC. Aerosolized drug delivery in the 90s. *Chest.* 1996 Aug;110(2):316-7. No abstract available.

23: Iacono AT, Keenan RJ, Duncan SR, Smaldone GC, Dauber JH, Paradis IL, Ohori NP, Grgurich WF, Burckart GJ, Zeevi A, Delgado E, O'Riordan TG, Zendarsky MM, Yousem SA, Griffith BP. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. *Am J Respir Crit Care Med.* 1996 Apr;153(4 Pt 1):1451-5.

24: Smaldone GC. Factors in measurement of dose by gamma scintigraphy. *J Aerosol Med.* 1996 Mar;9 Suppl 1:S69-76.

25: Diot P, Palmer LB, Uy LL, Albulak MK, Bonitch L, Smaldone GC. Technique for measurement of oropharyngeal clearance in the elderly. *J Aerosol Med.* 1995 Summer;8(2):177-86.

26: Cabahug CJ, McPeck M, Palmer LB, Cuccia A, Atkins HL, Smaldone GC. Utility of technetium-99m-DTPA in determining regional ventilation. *J Nucl Med.* 1996 Feb;37(2):239-44.

27: Palmer LB, Smaldone GC, Simon S, O'Riordan T, Morra L. Tracheal aspirates in long-term mechanically ventilated patients. A human model of gram-negative infection and airway inflammation. *Chest.* 1995 Nov;108(5):1326-32.

28: Diot P, Morra L, Smaldone GC. Albuterol delivery in a model of mechanical ventilation. Comparison of metered-dose inhaler and nebulizer efficiency. *Am J Respir Crit Care Med.* 1995 Oct;152(4 Pt 1):1391-4.

29: Diot P, Rivoire B, Le Pape A, Lemarie E, Dire D, Furet Y, Breteau M, Smaldone GC. Deposition of amphotericin B aerosols in pulmonary aspergilloma. *Eur Respir J.* 1995 Aug;8(8):1263-8.

30: O'Riordan TG, Iacono A, Keenan RJ, Duncan SR, Burckart GJ, Griffith BP, Smaldone GC. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. *Am J Respir Crit Care Med.* 1995 Feb;151(2 Pt 1):516-21.

#### Steinman, Charles

1: Steinman CR. Broad-range bacterial polymerase chain reaction for identification of bacteria in inflamed joints: comment on the article by Wilbrink et al. *Arthritis Rheum.* 1998 Dec;41(12):2276-9.

2: Yu D, Mukai M, Liu Q, Steinman CR. Specific inhibition of PCR by non-extendable oligonucleotides using a 5' to 3' exonuclease-deficient DNA polymerase. *Biotechniques.* 1997 Oct;23(4):714-6, 718-20.

3: Yu D, Rumore PM, Liu Q, Steinman CR. Soluble oligonucleosomal complexes in synovial fluid from inflamed joints. *Arthritis Rheum.* 1997 Apr;40(4):648-54.

4: Steinman CR, Muralidhar B, Nuovo GJ, Rumore PM, Yu D, Mukai M. Domain-directed polymerase chain reaction capable of distinguishing bacterial from host DNA at the single-cell level: characterization of a systematic method to investigate putative bacterial infection in idiopathic disease. *Anal Biochem.* 1997 Jan 15;244(2):328-39.

### Steigbigel, Roy

1: Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. *J Acquir Immune Defic Syndr.* 2000 Dec 1;25(4):312-21.

2: Mynarcik DC, Frost RA, Lang CH, DeCristofaro K, McNurlan MA, Garlick PJ, Steigbigel RT, Fuhrer J, Ahnn S, Gelato MC. Insulin-like growth factor system in patients with HIV infection: effect of exogenous growth hormone administration. *J Acquir Immune Defic Syndr.* 1999 Sep 1;22(1):49-55.

3: McNurlan MA, Garlick PJ, Frost RA, Decristofaro KA, Lang CH, Steigbigel RT, Fuhrer J, Gelato M. Albumin synthesis and bone collagen formation in human immunodeficiency virus-positive subjects: differential effects of growth hormone administration. *J Clin Endocrinol Metab.* 1998 Sep;83(9):3050-5.

4: Steigbigel RT, Benach JL. Immunization against Lyme disease--an important first step. *N Engl J Med.* 1998 Jul 23;339(4):263-4.

5: Gnann JW Jr, Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF, Borucki MJ, Joseph WP, Mertz GJ, Steigbigel RT, Cloud GA, Soong SJ, Sherrill LC, DeHertogh DA, Whitley RJ. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group. *Antimicrob Agents Chemother.* 1998 May;42(5):1139-45.

6: Morrison SA, Pearson SL, Steigbigel RT. Anti-F(ab')<sub>2</sub> antibody in HIV type 1 infection: relationship to hypergammaglobulinemia and to antibody specific to the V3 loop region of glycoprotein 120. *AIDS Res Hum Retroviruses.* 1998 Apr 10;14(6):491-8.

7: McNurlan MA, Garlick PJ, Steigbigel RT, DeCristofaro KA, Frost RA, Lang CH, Johnson RW, Santasier AM, Cabahug CJ, Fuhrer J, Gelato MC. Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease. *J Clin Invest.* 1997 Oct 15;100(8):2125-32.

- 8: Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H, Emini EA. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. *J Virol.* 1996 Dec;70(12):8270-6.
- 9: Becker JL, Steigbigel RT, Nuovo GJ. In situ detection of PCR-amplified HIV-1 and EBV nucleic acids in hyperplastic lymph nodes and in AIDS-related lymphoma. *J Histochem Cytochem.* 1996 Oct;44(10):1085-9.
- 10: Moorjani H, Craddock BP, Morrison SA, Steigbigel RT. Impairment of phagosome-lysosome fusion in HIV-1-infected macrophages. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996 Sep;13(1):18-22.
- 11: Cohen AJ, Steigbigel RT. Eosinophilia in patients infected with human immunodeficiency virus. *J Infect Dis.* 1996 Sep;174(3):615-8.
- 12: Lake-Bakaar G, Elsagr M, Hagag N, Lyubsky S, Ahuja J, Craddock B, Steigbigel RT. Changes in parietal cell structure and function in HIV disease. *Dig Dis Sci.* 1996 Jul;41(7):1398-408.
- 13: Handley MA, Steigbigel RT, Morrison SA. A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. *J Virol.* 1996 Jul;70(7):4451-6.
- 14: Kessler HA, Hurwitz S, Farthing C, Benson CA, Feinberg J, Kuritzkes DR, Bailey TC, Safrin S, Steigbigel RT, Cheeseman SH, McKinley GF, Wettlaufer B, Owens S, Nevin T, Korvick JA. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996 Jun 1;12(2):147-52.
- 15: Cohen OJ, Pantaleo G, Holodniy M, Fox CH, Orenstein JM, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, Cohn J, Novak R, McMahon D, Bilello J, Fauci AS. Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. *J Infect Dis.* 1996 Apr;173(4):849-56.
- 16: Fischl MA, Finkelstein DM, He W, Powderly WG, Triozzi PL, Steigbigel RT. A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996 Apr 1;11(4):379-84.
- 17: Nuovo GJ, Simsir A, Steigbigel RT, Kuschner M. Analysis of fatal pulmonary hantaviral infection in New York by reverse transcriptase in situ polymerase chain reaction. *Am J Pathol.* 1996 Mar;148(3):685-92.

18: Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, et al. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. *Proc Natl Acad Sci U S A*. 1995 Jun 20;92(13):6017-21.

Van Nostrand, William

1: Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic Effects of D23N Iowa Mutant Amyloid beta -Protein. *J Biol Chem*. 2001 Aug 31;276(35):32860-6.

2: Van Nostrand WE. Cellular and transgenic animal models of cerebrovascular amyloidosis. *Mol Med Today*. 2000 Sep;6(9):373-4.

3: Mahdi F, Rehemtulla A, Van Nostrand WE, Bajaj SP, Schmaier AH. Protease nexin-2/Amyloid beta-protein precursor regulates factor VIIa and the factor VIIa-tissue factor complex. *Thromb Res*. 2000 Aug 1;99(3):267-76.

4: Wagner MR, Keane DM, Melchor JP, Auspaker KR, Van Nostrand WE. Fibrillar amyloid beta-protein binds protease nexin-2/amyloid beta-protein precursor: stimulation of its inhibition of coagulation factor XIa. *Biochemistry*. 2000 Jun 27;39(25):7420-7.

5: Verbeek MM, Van Nostrand WE, Otte-Holler I, Wesseling P, De Waal RM. Amyloid-beta-induced degeneration of human brain pericytes is dependent on the apolipoprotein E genotype. *Ann N Y Acad Sci*. 2000 Apr;903:187-99.

6: Van Nostrand WE, Melchor J, Wagner M, Davis J. Cerebrovascular smooth muscle cell surface fibrillar A beta. Alteration of the proteolytic environment in the cerebral vessel wall. *Ann N Y Acad Sci*. 2000 Apr;903:89-96. Review.

7: Melchor JP, McVoy L, Van Nostrand WE. Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein. *J Neurochem*. 2000 May;74(5):2209-12.

8: Melchor JP, Van Nostrand WE. Fibrillar amyloid beta-protein mediates the pathologic accumulation of its secreted precursor in human cerebrovascular smooth muscle cells. *J Biol Chem*. 2000 Mar 31;275(13):9782-91.

9: Davis J, Cribbs DH, Cotman CW, Van Nostrand WE. Pathogenic amyloid beta-protein induces apoptosis in cultured human cerebrovascular smooth muscle cells. *Amyloid*. 1999 Sep;6(3):157-64.

10: Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. *Biochemistry*. 1999 Aug 31;38(35):11570-6.

11: Hook VY, Sei C, Yasothornsrikul S, Toneff T, Kang YH, Efthimiopoulos S, Robakis NK, Van Nostrand W. The kunitz protease inhibitor form of the amyloid precursor protein (KPI/APP)

inhibits the proneuropeptide processing enzyme prohormone thiol protease (PTP). Colocalization of KPI/APP and PTP in secretory vesicles. *J Biol Chem*. 1999 Jan 29;274(5):3165-72.

12: Meckelein B, Marshall DC, Conn KJ, Pietropaolo M, Van Nostrand W, Abraham CR. Identification of a novel serine protease-like molecule in human brain. *Brain Res Mol Brain Res*. 1998 Apr;55(2):181-97.

13: Bornebroek M, von dem Borne PA, Haan J, Meijers JC, Van Nostrand WE, Ross RA. Binding of amyloid beta precursor protein to coagulation factor XIa in vivo may favour haemorrhagic stroke. *J Neurol*. 1998 Feb;245(2):111-5.

14: Van Nostrand WE, Melchor JP, Ruffini L. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. *J Neurochem*. 1998 Jan;70(1):216-23.

15: Zhang Y, Scandura JM, Van Nostrand WE, Walsh PN. The mechanism by which heparin promotes the inhibition of coagulation factor Xia by protease nexin-2. *J Biol Chem*. 1997 Oct 17;272(42):26139-44.

16: Verbeek MM, de Waal RM, Schipper JJ, Van Nostrand WE. Rapid degeneration of cultured human brain pericytes by amyloid beta protein. *J Neurochem*. 1997 Mar;68(3):1135-41.

17: Scandura JM, Zhang Y, Van Nostrand WE, Walsh PN. Progress curve analysis of the kinetics with which blood coagulation factor Xia is inhibited by protease nexin-2. *Biochemistry*. 1997 Jan 14;36(2):412-20.

18: Davis J, Van Nostrand WE. Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. *Proc Natl Acad Sci U S A*. 1996 Apr 2;93(7):2996-3000.

19: Van Nostrand WE, Davis-Salinas J, Saporito-Irwin SM. Amyloid beta-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. *Ann N Y Acad Sci*. 1996 Jan 17;777:297-302. Review.

### Viola, Michael

1. Madajewicz S, Hentschel P, Burns P, Caruso R, Fiore J, Fried M, Malhotra H, Ostrow S, Sugarman S, Viola M. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. *J Clin Oncol*. 2000 Oct 15;18(20):3553-7.

### Vlay, Stephen

1: Vlay SC, Lawson WE. Demonstration of myocardial ischemia by an internal loop recorder. *Pacing Clin Electrophysiol*. 2000 Oct;23(10 Pt 1):1576-8.

Wadhwa, Nand

1: Leake R, Friend R, Wadhwa N. Improving adjustment to chronic illness through strategic self-presentation: an experimental study on a renal dialysis unit. *Health Psychol.* 1999 Jan;18(1):54-62.

2: Suh H, Peresleni T, Wadhwa N, McNurlan M, Garlick P, Goligorsky MS. Amino acid profile and nitric oxide pathway in patients on continuous ambulatory peritoneal dialysis: L-arginine depletion in acute peritonitis. *Am J Kidney Dis.* 1997 May;29(5):712-9.

Wertheim, William

1: Wertheim WA. Perioperative risk. Review of two guidelines for assessing older adults. *American College of Cardiology and American Heart Association. Geriatrics.* 2000 Jul;55(7):61-6; quiz 69.